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ABSTRACT
Arkan, Ethar. M.S., Physiology and Neuroscience, Wright State University, 2017. The
effect of aging on the blood brain barrier permeability and response to fluoxetine
enantiomers.
We tested the effect of the fluoxetine enantiomers (S-fluoxetine and R-fluoxetine)
versus Prozac (50:50 ratio of R- and S- fluoxetine enantiomers) and/or control on blood
brain barrier (BBB) permeability in different brain regions in both male and female rats.
The rats consumed orally the drug (5 mg/kg) or vehicle for a total of three days, then
were injected with sterile Evans blue dye ip, at least 12 hours before euthanasia.. We
see significant regional brain differences in BBB permeability (hippocampus has tighter
BBB), significant differences based on the age of the animals (young rats show
enhanced permeability in lower brain region), and significant differences based on the
sex of animals interacting with specific regional differences in BBB permeability
(female rats have enhanced permeability in cerebellum). We also see some effect of
the fluoxetine enantiomers, with S-fluoxetine enhancing permeability, and R fluoxetine
reducing permeability.
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BACKGROUND
Among elderly people worldwide, neurodegenerative diseases are the major cause of
disability and premature death. The most common neurodegenerative diseases include
Alzheimer’s disease, vascular dementia, frontotemporal dementia, Parkinson disease and
Huntington’s disease (1).
Neurodegeneration is defined as a progressive loss of neuronal structure and function,
which eventually leads to neuronal cell death. It is an important component of age-related
pathology. Neurodegenerative diseases begin in mid-life. They are characterized by motor
and/or cognitive symptoms that worsen with age, and its symptoms reduce the life
expectancy (2). In addition, genetic and environmental factors play a critical role in
neurodegenerative diseases development (3, 4), such as Amyotrophic lateral sclerosis
(ALS) (5). There are many possible causes for the neurodegenerative diseases. In this
study, we are focusing mainly on the changes in the blood brain barrier permeability due
to aging.
A tight blood brain barrier is important to keep out peripheral immune cells that may
attack and kill cells in the brain. It is critical to regulate the blood brain barrier permeability
to ensure a stable environment and an optimal ionic composition that are significant for
neural function and synaptic signaling functions. For example, the concentration of
potassium is maintained at 4.5 mM in mammalian plasma but it is maintained around 2.52.9 mM in cerebrospinal fluid (CSF) and brain interstitial fluid (ISF) in spite of changes
that occur after having a meal or exercise (6, 7). Also, the blood brain barrier helps to
regulate the amount of neurotransmitters in the blood and it keeps the neurotransmitters in
the central and peripheral nervous system separate. For example, blood plasma contains a
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high level of neuroexcitatory amino acid glutamate, which if increased in the brain could
result in a considerable neurotoxic damage in the neural tissue (8, 9). The blood brain
barrier regulates the entry of many macromolecules because high level of certain plasma
proteins could lead to nervous tissue damage. For example, high levels of plasma proteins
such as albumin, pro-thrombin, and plasminogen cause cellular activation that results in
apoptosis and nervous tissue damage (10, 11). For example, thrombin entry into the brain
will cause the potentiation of NMDA receptor that will result in glutamate-mediated cell
death (12).
The blood brain barrier (BBB) has low permeability to essential water soluble nutrients
and metabolites that are important for the nervous tissue’ however it has transport systems
in the BBB to ensure the supply of nutrients to the central nervous system (8, 13, 14).
Understanding how the BBB changes in permeability with age and in the presence of
enantiomers of fluoxetine may provide new approaches to treat the chronic
neurodegenerative diseases in the elderly human population that are currently without
effective treatment (2). Fluoxetine is used to treat neurodegenerative diseases because of
its ability to convert harmful microglia to beneficial microglia, a new role discovered in
the Corbett lab.
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I.INTRODUCTION
1.1 The Blood Brain Barrier
Paul Ehrlich was the first one to identify the blood brain barrier. He injected basic dyes
into the circulatory system and found out that it did not stain the brain but it stained most
other organs. Therefore, a conclusion was made that the blood brain barrier separates the
central and the peripheral nervous system in order to maintain ion hemostasis state in the
CNS by regulating the entry of toxic and pathogenic substances in and out of the CNS
except for lipid soluble molecules (15). That separation is important to insure the integrity
of neural network connectivity and to insure the longevity of neurons. Also, maintaining
ion hemostasis is critical for neuron signaling (16).
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Figure1: The brain interfaces include the following: the blood brain barrier, the bloodCSF barrier, and the arachnoid barrier (17).
The choroid plexus is a structure that is located within the brain ventricles. It is
composed of monolayer of epithelial cells. These epithelial cells are derived from the
ependymal cells of the brain ventricles (18). Mitochondria are found in the choroid plexus
epithelial cells to provide energy that is needed for the active transport and secretion (19).
These epithelial cells are connected by the tight junctions in order to limit the paracellular
diffusion (20). From the capillaries total surface area in the brain, the epithelial surface area
of the microvilli in the choroid plexus is composed of about 25 to 50% of the total surface
4

area (21) . At the choroid plexuses, the blood flow rate is about five times more than the
blood flow rate at other brain regions (20).
The arachnoid barrier limits the exchange between the blood and the CNS because of its
avascular epithelium surface and its small surface area (17). The barrier is composed of
tight junctions. It functions as a physical barrier by separating the dural layer from the
cerebrospinal fluid that is found in the subarachnoid space. It is considered as the most
complex barrier among the different barriers of the brain (22-24). The arachnoid barrier is
found at the meninges of the brain under the dura layer of the brain (8).
1.2 Neurovascular Unit

Figure 2: Cellular elements of the BBB (2).
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“Modular” Neurovascular unit (NVU) is made of a capillary segment with basal lamina,
pericytes, perivascular astrocytes, and microglial cells (16). Also, different neurons types
(e.g. noradrenergic, serotonergic, cholinergic, GABAeric) have been observed to be part
of the neurovascular unit (25).
1.2.1 Microglia
The first one to describe microglia was the Spanish neuroanatomist Del Rio-Hortega.
The microglial cells represent about 20% of the total glial cell population within the CNS
(26). The microglial cells are characterized by a small cell body (5-10 µm) and they possess
many radial cell processes extending from the cell body. Branched microglia are involved
in extracellular fluid cleansing and neurotransmitter deactivation which contributes to the
maintenance of homeostasis. Microglial cells lack endocytic and phagocytic activity under
normal physiological conditions (27). Diseases or trauma could lead to microglial
activation, and this activation is directly correlated to the type and severity of brain injury
(28). Activated microglia have a relatively large cell body and short cytoplasmic processes.
Activated microglia secrete high levels of neurotoxic mediators such as nitric oxide,
peroxide, inflammatory cytokines, proteases and complement components (28, 29).
Excessive production of these substances further lead to cell injury in the CNS which in
turn leads to astrocyte activation which leads to further microglial activation. That will
eventually lead to neuronal cell death (25). Dysfunction of the BBB is characterized by
changes in tight junction protein expression and enhanced paracellular permeability which
is directly associated with the activation of microglia (30). The microglial functional state
determines the expression of ion channels in the microglia (31-34). There are several ion
channels in the microglia including multiple potassium, calcium, sodium and chloride
6

channels (35). In addition, microglia express glutamate receptors (36) and transporters such
as GLUT-1 (37). Furthermore, these cells express membrane proteins, which are involved
in drug transport. The microglial cells are involved in a variety of physiological functions
including proliferation, ramification and maintenance of membrane potential. They are also
involved in intracellular pH regulation and cell volume regulation (31-34) .
1.2.2 The Basement Membrane
The basement membrane (BM) is an important component of the neurovascular unit. It
surrounds all the cerebral capillaries (38). Collagen type IV, I, fibronectin, thrombospondin
(39), laminin, nidogen, heparin sulfate proteogltcans, and agrin (40) are the main
components of the basement membrane. There are two types of the basement membrane.
The vascular basement membrane and the parenchymal basement membrane. The vascular
basement membrane is an extracellular matrix secreted by the endothelial cells and
pericytes and it contains laminins a4 and a5. In contrast, the parenchymal basement
membrane is secreted by astrocytic processes and it contains laminins a1 and a2 (41, 42).
The basement membrane plays an important role as an anchor for signaling processes at
the vasculature and it provides an additional barrier for molecules and cells to cross before
accessing the neural tissue. BBB dysfunction and leukocyte infiltration during the
neurodegenerative diseases can result from the disruption of the basement membrane by
matrix metalloprotienases (43).
1.2.3 Endothelial Cells (ECs)
Endothelial cells are simple squamous epithelial cells that line the interior of all blood
vessels. They are derived from the mesoderm layer (44, 45). The phenotypic characteristics
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of the ECs depend primarily on the location of the ECs. The CNS endothelial cells are very
thin cells: they are 39% less thick (46) than the vascular endothelial cells that are found in
the skeletal muscle (43). They make the inner walls of the blood vessels by folding onto
itself to form the lumen of the vessel. Endothelial cells are considered as the major cell that
is responsible for the blood brain barrier integrity. They regulate the CNS homeostasis by
providing a combination of a physical barrier, and a molecular barrier. The endothelial
cells that forms the BBB are characterized by having a high numbers of mitochondria that
are essential to generate ATP in order to transfer the ions across the the cells using
transporters. Also, they are characterized by lacking fenestrations in their cell membrane
and having a reduced pinocytotic activity. The endothelial cells limit the paracellular
movement of solutes at the BBB by forming intercellular tight junctions (22, 47, 48). In
addition, they limit the transcellular movement of solutes by limiting the vesicle-mediated
transcellular movement of solutes. Furthermore, they express very low level of leukocyte
adhesion molecules in order to limit the amount of immune cells that enter the CNS (43,
49, 50). There two main categories of transporters are found in the CNS endothelial cells.
At the luminal surface of the endothelia are found the efflux transporters which transport
the lipophilic molecules (51-53). Highly specific nutrient transporters are the second type
of transporters which transport nutrients across the BBB into the CNS and remove the
waste products from the CNS into the blood (54).
1.2.4 Astrocytes
Astrocytes are the most abundant glial cell type in the brain. The astrocytic end feet
contain an array of proteins including connexins, dystroclycan, dystrophin, and aquaporin
4 that surround the cerebral capillaries of the brain (43). The close proximity of the
8

astrocytic end feet to the capillary network and its close relation to the neuron makes the
astrocytes participate in a significant role to ensure development and maintenance of the
BBB. The astrocytes maintain the metabolic and the nutritive support of the neuron (15).
The endfeet of the astrocyte is linked to the basement membrane by the dystroglycandystrophin complex by binding agrin (43). This linkage is critical to place aquaporin 4 in
a position to regulate water homeostasis in the CNS. Also, astrocytes disperse vascular
nutrients away from the blood vessel in support of neuron in that region. Astrocytes induce
tight junction formation by secreting soluble factors (15) . Some of the examples of the
glial derived factors that are secreted by the astrocytes and result in the induction of the
BBB phenotype in endothelial cells include: transforming growth factor (55), aniopoetin
1, basic fibroblast growth factor, and glial derived neurotrophic factor (56).
Astrocytes act as a cellular link between the capillaries and the neurons. That link is
significant to regulate the contraction/dilation of vascular muscle cells that surround the
capillaries by responding to changes in neuronal activity (43). Moreover, astrocytes
participate in the regulation of cerebral microvascular permeability via Ca signaling (57,
58). In addition, astrocytes have a high-affinity transporter for glutamate that contributes
to maintaining low excitatory neurotransmitter concentrations in the brain. Furthermore,
astrocytes act as a secondary barrier for CNS drug permeation by preventing the drug to
reach their action site either by sequestering the drug within the astrocyte cytoplasm or by
keeping the drugs at the brain extracellular fluids (25).
1.3 Tight Junction
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Figure 3: Tight junction proteins (25). ZO-1 stands for zona occludin protein-1. 7H6 stands
for cytoplasmic tight junction-associated protein (59). AF-6 stands for afadin (60).
The tight junction is an almost impermeable continuous barrier that interconnects the
BBB endothelial cells to prevent the entry of foreign substances with the exception of small
lipid-soluble molecules (61). Tight junctions are formed by transmembrane proteins which
include occludin, claudins, junction adhesion molecules (JAMs) that are connected to the
cytoskeleton through accessory proteins (e.g., zonula occlude 1, 2, and 3) (62).
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Figure 4: Basic Structure of selected tight junction proteins (63).
Occludin is considered as the first identified membrane protein within the tight junction.
It consists of four transmembrane domains, two extracellular domains, and three
cytoplasmic domains. It has a molecular weight of 60-65 kDa (64). It has two extracellular
loops that span the intercellular cleft and are separated by a short cytoplasmic loop. The
amino (N-terminus) and carboxy (C-terminus) are both cytoplasmic terminal domains (65).
Claudins are 20-24 KDa proteins (62). They have a similar basic structure to occludin,
with much smaller cytoplasmic chains (65). It forms that primary “seal” of the tight
junction (25). Junctional adhesion molecules (JAM) has several isoforms at the BBB
including junction adhesion molecules-1 (JAM-1), junction adhesion molecules-2 (JAM2) and junction adhesion molecules-3 (JAM-3) (62, 66). Junctional adhesion molecules-1
(JAM-1) is 40-KDa, and it play a role in the early developmental stages of the BBB.
Junctional adhesion molecules-1 (JAM-1) mediates the early attachment of endothelial
cells during the development of the BBB (67). Moreover, it regulates the transendothelial
migration of leukocytes during inflammation (66). Loss of junctional adhesion molecules
11

(JAM) protein expression is correlated with BBB breakdown (68, 69) but it is not a
sufficient marker for the BBB breakdown (70).
Accessory proteins including Membrane-associated guanylate kinase-like (MAGUK)
family, cingulin, AF-6, 7H6 and EMP-1 (62, 71) are involved in coordination and
clustering of tight junction protein complexes to the cell membrane (72). Three proteins of
the membrane-associated guanylate kinase-like (MAGUK) family have been identified at
the tight junction: ZO-1, -2, and -3. The protein that was directly involved with tight
junction complexes is ZO-1 (73). It connects the transmembrane proteins of the tight
junction to the actin cytoskeleton (74). In addition, ZO-1 acts as a signaling molecule that
communicates the state of the tight junction to the cellular interior (75). ZO-2 is a protein
that binds structural tight junction constituents, signaling molecules and transcription
factors (76). ZO-3 function is still not known yet (25).

Figure 5: the structure of connexin 43 (77).

12

Connexins have many different types (at least twenty-one) that are named according to
their molecular weights. The above figure represents the structure of connexin 43. About
150 amino acids form the structure of the connexin’s C-terminus (78, 79). Arginine,
aspartic acid, asparagine, serine and proline are the most common amino acids that are
found in the connexine 43. Protein interactions and kinases target the proline and serines
composition of the connexin 43 (80). It is made of four transmembrane segments with two
extracellular loops and one intracellular loop. Also, two terminals that are found in the
cytosol: an amino terminal and a carboxy terminal that has multiple phosphorylation sites
as figure shows it. Hemichannel is formed by six connexin that surrounds the aqueous pore.
Two hemichannels form the gap junctions (77). Cell to cell communication occurs through
gap junction (81) that allows cytoplasmic contents to passes through the opening of the
hemichannels to the extracellular fluid. Gap junctions are considered as a dynamic structure
because of cell ability to modify the number of the gap junctions through connexins
biosynthesis, degradation and endocytosis (81). Some of the integral membrane proteins
show half-lives of more than 75hrs (82, 83). In contrast, some other integral membrane
proteins has a half-life of less than 5hrs (82-84). Regarding connexin degradation, it has a
half-life of 1.5-5 hours. It shows that half-life in both vivo and in cultured cells (85-87).
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Figure 6: phosphorylation sites at the connexin carboxy terminus (88).
1.4 Transport across the BBB

Figure 7: Transport across the BBB (89).
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There are several ways to transport across the blood brain barrier. Passive diffusion
(membrane transport in Figure 5) is for small lipophilic molecules with a molecular weight
less than 500 Da (90, 91). An example of small molecules that passively diffuse through
the cell membrane are barbiturates, ethanol, and caffeine. Also, gaseous lipophilic
molecules can diffuse through the cell membrane such as O2 and CO2 (92, 93). Carriermediated transport is for small polar molecules, such as glucose, amino acids, organic
anions and cations, and nucleosides (94). Large molecules and 98% of all small molecules
do not cross the BBB (92, 93). Previous studies have shown that catecholamines do not
cross the blood brain barrier (95).
1.5 BBB Disruption
Any disturbance to the function of these proteins will results in destabilizing the junctions,
and it will enhance the paracellular diffusion. In the basal region of the lateral plasma
membranes, there are adherens junctions below the tight junctions. Catenins connect
cadherins to the cytoskeleton, and cadherins stabilize adhesion between basal endothelial
cells in the adherens junctions.
Any disruption to the blood brain barrier permeability could lead to many central nervous
system diseases such as Alzheimer’s disease, amyotrophic lateral sclerosis,
cerebrovascular disease (e.g. stroke), epilepsy, seizures, brain infection, meningitis,
inflammatory disease, brain tumors, neurotrauma (89). Changes in ion balance, disrupting
transport systems, and alternating the enzymatic barrier from being effective could be the
results from BBB dysfunction. The blood brain barrier has tight junctions which limits the
entry of certain molecules such such polar molecules and large molecules. Also, it limits
15

the entry of solute carrier protein along with ectoenzyme and endoenzyme that is found
inside the endothelial cells. Therefore, it functions as an enzymatic (metabolic barrier) (16).

Figure 8: causes, characteristics, and consequences of BBB breakdown (5).
As the above figure shows that there are several factors that could lead to the blood brain
barrier breakdown. Examples for the different causes that could cause the blood brain
barrier

permeability

include

the

following:

reactive

oxygen

species,

matrix

metalloproteinases (MMPs), angiogenic factors, inflammatory cytokines, autoantibodies,
leukocyte adhesion, immune cell extravasation and pathogens. The characteristics of the
blood brain barrier breakdown include the following: increased permeability, reduced tight
junction protein expression and redistribution, impaired transporter function, insufficient
clearance function, pericyte detachment, astrocyte loss and a disrupted basement
membrane. The blood brain barrier breakdown leads to the following: imbalance of ions,
leakage of plasma protein, entry of toxins, microglial activation and release of cytokines
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and chemokines. That will eventually lead to neuronal dysfunction, inflammation and
degeneration.
Previous studies have indicated that it is not certain yet that the blood brain barrier
disruption is always caused by or a consequence of the oxidative stress (5). Nevertheless,
some neurological diseases have blood brain barrier disruption associated with oxidative
stress such as stroke, multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS) (9698). Oxidative stress refers to having many reactive oxygen species (ROS) that are more
than necessary or required, possibly because of a damaged intrinsic antioxidant defense
system. There are several mechanisms by which elevated reactive oxygen species could
lead to the BBB dysfunction. One of the mechanisms is that the reactive oxygen species
could cause destruction and damage to the cellular molecules such as proteins, lipids and
DNA.

Other mechanisms include the following: increasing the response to the

inflammatory mediators, damaging the tight junction proteins, causing cytoskeletal
reorganization and causing the activation of the matrix metalloproteinases (MMPs) (99).
Blood brain barrier disruption could lead to an abnormal neuronal activity that is caused
by the imbalance of certain molecules in the interstitial fluid (e.g. ions, transmitters and
metabolic products). An example of this situation occurs in seizures. Several neurological
diseases have seizures such as epilepsy, central nervous system infections, stroke and
neurodegenerative diseases (100). It is not known yet if epilepsy is a cause or a
consequence of damaged blood brain barrier (101). Inflammation could lead to
neurological diseases by causing a blood brain barrier disruption. An example of this
situation is the neurological disease neuromyelitis optica (NMO). It is an inflammatory
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disease that attack the central nervous system. It mainly affects the spinal cord and the optic
nerve (102).
The table below lists the blood brain barrier disruption as either a primary or a
secondary result of certain diseases.
Diseases linked to BBB dysfunction
Disease

Level of
BBB
effect

Stroke

Primary

Comment

Microvascular injury induced by oxidative stress during
ischemia/reperfusion

Epilepsy

Systemic inflammation can disturb brain homeostasis by
allowing entry of ions and epileptogenic substances
across the BBB
Seizures reduce BBB integrity, which enables entry of
Secondary plasma proteins into the brain that sustain the
epileptogenic state

AD

Primary

BBB dysfunction, including defective amyloid-beta
clearance from brain and congophilic angiopathy

Familial
ALS

Primary

Loss of BBB integrity at an ultrastructural level,
associated with expression of mutant SOD1 in brain
capillary endothelial cells

PD

Increased BBB permeability and decreased transport
Secondary activity across the BBB, including inefficient efflux of
toxic molecules via P-glycoprotein

MS

Secondary

Primary

Extravasation of autoreactive T cells and monocytes
across a compromised BBB

Natalizum
Infiltration of T cells in perivascular space and
ab-PML with Secondary parenchyma after discontinuation of Natalizumab in
IRIS
context of PML
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Disease

Level of
BBB
effect

Comment

NMO

Primary

BBB breakdown including loss of AQP4 and of
astrocytes caused by AQP4-IgG

Primary
CNS
vasculitis

Primary

Inflammation of cerebral vessels without systemic
disorder

Secondary
CNS
vasculitis

Primary

Inflammation of cerebral vessels associated with
systemic inflammatory illness

VZV
Primary
vasculopathy

Viral infection (primary or upon reactivation) of cerebral
arteries

Cerebral
malaria

Primary

Sequestration of parasitized red blood cells in lumen of
cerebral microvasculature

Primary
CNS
lymphoma

Secondary Leaky angiogenic vessels in malignant tissue

Leaky neo-angiogenic vessels and loss of BBB integrity
Glioblastoma Secondary in pre-existing vessels (by subcellular mislocalization of
astroglial AQP4) in malignant tissue

PRES

Primary

Vascular injury by systemic influence, such as disorders
of clotting or bleeding, and chemotherapy agents
(particularly those which inhibit VEGFR kinase)

TBI

Secondary

Mechanical disruption of BBB followed by posttraumatic BBB dysfunction

Migraine

Secondary

Cortical spreading depression with subsequent vascular
reaction

Diabetes

Secondary

Increased BBB permeability, possibly leading to
cognitive impairment
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*

Primary level of BBB effect indicates that the cerebrovasculature is probably
compromised upstream from CNS pathogenesis whereas secondary level of BBB effect is
interpreted as happening downstream from the initial insult and aggravating disease.
AD, Alzheimer’s disease; ALS, Amyotrophic lateral sclerosis; PD, Parkinson’s disease;
MS, Multiple sclerosis; PML, Progressive multifocal leukoencephalopathy; IRIS,
Immune reconstitution inflammatory syndrome; NMO, Neuromyelitis optica; VZV,
Varizella zoster virus; PRES, Posterior reversible encephalophathy syndrome; TBI,
Traumatic brain injury
Table 1: Diseases and blood brain barrier disruption (5).
Table 2. Changes in the BBB constituents with aging (2).
BBB elements

Properties

ECs

Capillary wall thickness: increased in humans decreased in rats
decreased in monkeys Number of ECs: decreased in humans
Number of mitochondria: decreased

Tight junctions

Expression of tight junction proteins: decreased

Basal lamina

Thickness of basement membrane: Increased
Concentration of collagen IV and agrin: Increased
Concentration of laminin: decreased

Astrocytes

Astrocyte proliferation: Increased number and
size
GFAP expression: Increased

Microglia

Changes to amoeboid morphology
Production of neurotoxic proinflammatory mediators

Pericytes

Number of pericytes: Degeneration and loss of pericytes
Ultrastructural changes: vesicular and lipofuscin-like
inclusions, increased size of mitochondria, foamy
transformation

Neurons

Deterioration of synaptic plasticity Deficit in long-term
potentiation Impaired neurogenesis. Increased apoptosis,
Neuronal damage due cytokine release
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The above table lists the changes that occur in the blood brain barrier permeability with
aging (2). We see that the tight junction proteins are decreased with age. Also, we noticed
more neuronal damage with age caused due to cytokine release. Most of the animal models
used in the above table were mice.
1.6 Fluoxetine
Fluoxetine is (R, S)-N-methyl-3-phenyl-3-(4-(trifluoromethyl) phenoxy) propan-1amine. It is the first selective serotonin uptake inhibitor approved by the United States Food
and Drug Administration (FDA)(103). It is used to treat diseases that are related to the
Central Nervous System. For examples, it is used to treat major depressive disorder,
obsessive-compulsive disorder, acute depressive episodes in Bipolar I disorder, panic
disorder bulimia nervosa, and premenstrual dysphoric disorder (104),

Figure 9: Chemical Structure of Fluoxetine (105).
1.6.1 Fluoxetine Metabolism
Fluoxetine has the largest volume of distribution among SSRI drugs. Fluoxetine
has a long half-life and low plasma protein binding. It takes between 1 and 22 months to
achieve steady state due to its long half-life according to depression studies. Also, it is
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almost completely absorbed following oral administration. High performance liquid
chromatography (HPLC) was used to detect the presence of fluoxetine and its active
metabolites in the serum and the brain of the Sprague Dawley rats after drug ingestion
(106, 107).
Fluoxetine is metabolized in the liver by cytochrome P450 that results in forming different
metabolites.

Figure 10: Structures of the oxidative and conjugative metabolites of fluoxetine. The major
metabolite is norfluoxetine, equipotent to fluoxetine for the S-enantiomer but with a
significantly longer half-life than fluoxetine 1. The phenolic metabolite is inactive. The
single enantiomers (S)-1 and (R)-1 showed divergent 2D6 metabolism (108) .
Fluoxetine is excreted as either norfluoxetine or as fluoxetine glucuronide or
norfluoxetine glucoronide. The norfluoxetine metabolite is formed mainly by CYP2D6
while the inactive phenolic metabolite 14 is formed by CYPs 2C19.

Norfluoxetine is

pharmacologically similar to fluoxetine for the S-enatiomer, but not the R-enantiomer, yet
it has a longer half-life (4-16 days). Fluoxetine is both a substrate and an inhibitor of
CYP2D6 while norfluoxetine is both substrate and an inhibitor of CYP3A4.
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Both

Fluoxetine and norfluoxetine have R and S enantiomers. (S)-fluoxetine is 1.5 times more
potent than (R)-fluoxetine while (S)-norfluoxetine is 5 to 20 times more potent than (R)norfluoxetine (108).
1.6.2 Fluoxetine Effect on Microglial cells
Neuroinflammation involves microglial activation (109). Pro-inflammatory factors which
include reactive oxygen species, chemokines and cytokines are secreted during microglial
activation. Neuronal damages occur due to the accumulation of the previous proinflammatory factors. Toxic soluble factors get released from the damaged neurons. These
toxic soluble factors amplify microglial activation. Hence, preventing the microglial
activation that is associated with neuroinflammation represent a therapeutic potential to the
neurological disorders that are caused by neuroinflammation. Fluoxetine has an important
role in neuroprotection. It inhibits the release of a microglial transcription factor, NF-KB
that results in the production of cytotoxic factors and proinflammatory factors. In addition,
fluoxetine decreases the morphological changes that are associated with activated
microglia. These changes involve a larger cell body, irregular shapes and thicker processes
(110). The fluoxetine exert its effect though affecting the immune system. It activates M2
through IL-4 induction and inhibits M1 through LPS + INF induction (111).

1.7 HYPOTHESIS
In this study, we predict that aging will cause more neurodegenerative diseases by
increasing the blood brain barrier permeability. Also, we expect that certain drugs such as
fluoxetine will change the blood brain barrier permeability by either making it tighter or
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by increasing its permeability. Each enantiomer of fluoxetine will have a different effect
on the permeability of the blood brain barrier. We expect that our results will match the
results of the stroke study. In stroke animals, our lab saw that R-fluoxetine is increased the
permeability while S-fluoxetine is decreased the permeability of the blood brain barrier.
However, this will be the first test of these enantiomers in a normal, uninjured brain. The
research study that was conducted by Dr. Debra’s Mayes by using an artificial blood brain
barrier found that R-fluoxetine tighten the blood brain barrier while S-fluoxetine loosen
the blood brain barrier.
1.7.1 Specific Aims
Specific Aim 1: The main aim of this study is to test the effect of Prozac
enantiomers (R-fluoxetine and S-fluoxetine) on the blood brain barrier permeability in
different brain regions (cortex, hippocampus, striatum-caudate putamen-hypothalamus
(brain), and the cerebellum). We chose the cortex and the hippocampus regions because
they are aged related regions that are associated with neurodegenerative diseases such as
Alzheimer. Previous stroke studies have chosen cerebellum region to study.
Specific Aim 2: We will determine if there are age and gender difference in the
blood brain barrier permeability across the different tested brain regions among the males
(at different ages) and females rats (at an older age). Males and females animals showed
no difference in blood brain barrier permeability as previous studies have shown (112).
During this study, we did not have enough funding to include young females.
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Specific Aim 3: We are comparing the results of this study in the discussion with
previous studies that have been conducted on stroke injured animals, to examine changes
in normal versus injured brains.
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II. MATERIALS AND METHODS
2.1 Voluntary Drug Administration
The purified R-enantiomer and S-enantiomer of 5mg/kg fluoxetine have been given
to the Sprague Dawley rats. Also, its 50/50 combined racemic mixture (trade name Prozac)
has been given to the young male rats at a dosage of 5mg/kg. Prozac was purchased from
a pharmacy while the enantiomers of fluoxetine were purchased from Sigma-Aldrich. The
drug Prozac is a combination of 50:50 R-fluoxetine/S-fluoxetine. Studies have shown that
subcutaneous drug administration could increase the level of stress to the animal by
increasing the level of stress hormones such as corticosterone, particular if the drugs need
to be administered on a daily basis (113). In order to reduce the amount of stress that the
animals might experience during this study, the medicine was delivered to the animal
encased in sugar cookie dough that weighted about 4 grams. The control animals were only
given the cookie dough without medicine. Each animal received the drugs for a total of 3
days and were euthanized on the fourth day.
The animals were injected ip with sterile 2% Evans blue in PBS (1 ml for young
animals; 2.5 mls for old animals) late on the third day of drug administration. During this
study, we had to give the animals the medicine first then injecting them with Evan’s blue
because the animals did not eat their medications if they were given Evans’ blue dye first.
After 12-16 hours later, the animals were euthanized, and cardioperfused.
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In order to avoid bias, randomization and blinding were applied during this study
(114). During this study, I did not know any information about the animal except their
numbers.

Figure 11: method for voluntary drug administration (113).
2.2 Euthanization
Intraperitoneal injection of Euthasol (100 mg/kg pentobarbital) was performed in
order to euthanize the animals. The tail-pinch method was applied to check the
consciousness of the rat. When the animal reached the stage of surgical anesthesia by
showing no pain reflexes, the animal was ready to go through the cardioperfusion
procedure.
2.3 Cardioperfusion
An incision was made at the diaphragm region extended to the upper thorax. We
basically removed a flap of the ribs covering the heart, so that the heart was fully exposed.
Then, a hemostat was placed at the apex of the heart and loosely held. A scissor was used
to cut the apex heart muscle held in the hemostat, and a cannula was pushed through into
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the left ventricle. After the perfusion needle (cannula) was inserted into the apex of the
heart, the hemostat was clamped. The perfusion needle was supplied with ice cold
phosphate buffered saline (PBS). The heart was slightly tilted toward the left to locate the
thinner right ventricle. Then, a cut was made at the right atria to let the blood flow out of
the body of the rat.
Brain Dissection
Once perfusion is completed, generally after 150 mls of buffer is passed through
the heart, we see a change in the color of the liver to a lighter color. The head of the rat
was decapitated. Then, the skin that covered the skull was removed starting from the base
of the skull near the spinal cord. A smooth curved rongeurs was slid under the skull bone,
around the midline of the skull. Then, it was lifted away from the brain to remove the skull,
and we made sure not to damage the brain tissue. A curved spatula was placed under the
anterior of the brain, near the olfactory bulbs and then the brain was lifted upward. The
optic nerves were cut and the brain was removed from the head of the rat. A microtome
blade was used to dissect the brain sections.
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Figure 12: Steps to dissect the rat brain (115).

The dissected brain sections, including the cortex, the peri-ventricular and
hippocampus region, the lower brain region (composed of the striatum-caudate putamenhypothalamus) and the cerebellum, were individually placed in a beaker filled with dry ice
and isopentane for about 10 sec to quick freeze the brain sections. The vials with these
quick frozen brain sections were weighed while they were empty and weighed again with
the brain tissue in order to find the weight (mg) of the dissected brain tissue.
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Evan’s Blue Protocol
A 50% trichloroacetic acid (TCA) stock solution is prepared by mixing 10 ml of
cerebrospinal fluid (ACSF) with 5 grams of TCA. Brain tissues were homogenized in 1:3
ACSF: TCA stock which was prepared by adding 375 µl of TCA stock solution and 125
µl of ACSF to every single brain section. Then, they were spun at 10,000 relative
centrifugal force for 20 minutes. The pellets and the supernatants were separated and have
been collected into different vials, and they were kept at the freezer with -80 degree Celsius.
Calibration Curve Solutions Preparations
Two stocks solutions were prepared in order to prepare the calibration standard.
The first stock solution is the 1:3 TCA solution which was prepared by mixing 1.25 ml of
the ACSF with 3.75 ml of TCA stock, described above. The second stock solution was 1
mg/ml Evans blue (for evans blue calibration curve) or 1 mg/ml bovine serum albumin
(BSA; for protein assay) dissolved in the 1:3 TCA solution (calibration stock).
Four test tubes were labeled with 0 µg/ml, 2 µg/ml, 5 µg/ml, and 10 µg/ml
sequentially. Then, 1ml of 1:3 TCA stock solution was added to the first tube, 2 µl of 1
mg/ml evans blue stock with 998 µl of 1:3 TCA were added to the second tube, 5 µl of 1
mg/ml evans blue stock with 995 µl of stock 1:3 TCA were added to the third tube, and 10
ul evans blue with 990 µl of 1:3 TCA were added to the last tube. Then, the test tubes were
mixed well and vortexed. These were the calibration curve stocks for Evans blue assay.
Microtiter plate Preparation
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Supernatants and homogenized pellets from each brain sample (four different
regions for each animal) were read using a microtiter plate. An empty blank sheets were
filled with the numbers and the labeling of the brain tissues in order to help with filling out
the real microtiter plate, using 3 replicates for each sample. Then 30 µl of each the
calibration stocks and each sample of the brain (supernatant or homogenized pellet) were
added to the microtiter plate (3 replicate wells for each). Later, 90 µl of 95% ethanol was
added to each well on the plate. The plates were taken to a spectrofluorometer microtiter
plate reader in order to be read. The fluorescence values for the spectrophotometer were
620nm for the excitation value and 680nm for the emission value. In order to determine
the number of nanograms of evans blue detected per milligram of brain tissue is available,
the standard calibration curve was analyzed for its slope and y-intercept. These values
were used to determine the number of nanograms of evans blue in each 30 ul brain sample,
using the formula:
Ng Evans blue = (average brain sample fluorescence- y intercept)/slope.
2.4 Pellet Homogenization
Two rat brain sample pellets were homogenized at the same time. First, 0.5 ml of
phosphate buffered solution (PBS) was added to the pellet. Then, the each pellet was
ground by using the PTFE pestle. Next, the pellet was homogenized by using a Tissumizer
rotor. After that, the pellet’s solution was transferred to a Dounce tissue grinder in order to
be thoroughly homogenized, breaking up all clumps of tissue. Later, another 0.5 ml of PBS
was added and the homogenized pellet was mixed by using the Tissumizer. After the pellet
is completely homogenized in a total of 1ml PBS, it was transferred with to a new vial and
labeled.
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2.5 Bradford Protein Assay
Bradford Solution Preparation
Bradford solution is prepared in steps: in the first step 100mg of Coomassie blue G
is mixed with 850 ml of distilled water overnight. That solution should be dark in color due
to the presence of Coomassie blue. In the second step, 50 ml of ethanol is added to the
solution and it will cause the solution to turn bright blue. Finally, 100 ml of phosphoric
acid (85%) is added to the solution and the solution is expected to turn brown.
Calibration Standard Stocks Preparation
Six test tubes will be labeled with the following numbers: 0 µg/ml, 1 µg/ml, 2
µg/ml, 5 µg/ml, 10 µg/ml, and 20 µg/ml. Then, 1ml of distilled water is added to the 0
µg/ml. Then, 20 µl of BSA with 980 µl were added to the 1 µg/ml labeled tube. Next, 40
µl of 1mg/ml BSA with 960 µl distilled water were added to 2 µg/ml labeled tube. Later,
100 µl of 1mg/ml BSA with 900 µl of distilled water were added to the 5 µg/ml labeled
tube. After that, 200 µl of 1mg/ml BSA with 800 µl of distilled water were added to the 10
µg/ml labeled tube. Finally, 400 µl of 1mg/ml BSA with 600 µl distilled water were added
to the 20 µg/ml labeled tube.
Pellets Dilution Preparation
At least two dilutions of each pellet were prepared for protein determination. The
dilution factor was determined based on the amount of the protein that was present in the
vial. Most of the time the dilution was 1:2 and 1:4 for the cortex, striatum-caudata putamen
and the cerebellum. For the peri-ventricular and hippocampus, the dilution was 1:1 and 1:2.

32

All brain pellets were homogenized into 1 ml of PBS before they were assayed for protein
content.
The 1:2 dilution stock was prepared by adding 75 µl of the homogenized pellet
sample with 75 µl of PBS while the 1:4 dilution was prepared by adding 50 µl of the
homogenized pellet sample with 150 µl of the PBS. Then, 50 µl of pellet dilution stock
was added to each of the two test tubes label with 1:1 dilution. After all the tubes are
completed, 50 µl of water was added to all the tubes. Two replicated was prepared for each
tube from the calibration stock solution by taking 50 µl from the calibration stock solution.
Then, 50 µl of PBS was added to each replicate to ensure that the chemical composition of
the protein in the standards and the protein in the samples is matched. Later, Bradford
solution was added to all of the test tubes. About 30 mins had passed until the
spectrophotometer reading were taken. First the blank test tube is placed inside the
spectrophotometer. While placing the spectrophotometer on transmission, the
spectrophotometer was zeroed by blocking transmission and then full transmission was set
to 100. Following this, the spectrophotomer was set to absorbance at 595 nm, and each
tube was read.
2.6 Animal Model
Sprague-Dawley rats males and females were used during this research study.
Young rats weighed 100gm (1.5 months) while the old male rats weighed about 500 grams
(10-12 months) and old female rats weighed about 300 grams. The rats were kept in cages
provided with water and ad libitum food. The animals were obtained from the laboratory
animal resource department. The research study was conducted in accordance with the
federal guidelines for the care and use of laboratory animals for scientific purposes.
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2.7 Statistical Analysis
Graph prism 7 software was used to determine the statistical differences between
the groups. One-way and two-way ANOVA were the statistical methods that have been
used in this research study. ROUT analysis was used to identify outliers.
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III. Results
In Table 1, the animal treatment groups used in this study are shown, with the
amount of drug they were given by voluntary oral administration for three days, and the
abbreviation that is used for that group. On the third day, after drug administration, animals
were injected ip with Evans blue and were euthanized and cardioperfused approximately
16-20 hours later. Since we only used Prozac in the young rats, we will only compare it to
the enantiomers of fluoxetine and the control in the young rats. Also we do not have a
young rat control for the female rats, so we will only compare male old rats with female
old rats to analyze for gender differences

Animal Age and Gender
Drug Treatment
Abbr.
1.5 month male rats
Control
CYM
1.5 month male rats
5 mg/kg S-fluoxetine
SYM
1.5 month male rats
5 mg/kg R-fluoxetine
RYM
1.5 month male rats
5 mg/kg Prozac
PYM
10 month male rats
Control
COM
10 month male rats
5 mg/kg S-fluoxetine
SOM
10 month male rats
5 mg/kg R-fluoxetine
ROM
10 month female rats
Control
COF
10 month female rats
5 mg/kg S-fluoxetine
SOF
10 month female rats
5 mg/kg R-fluoxetine
ROF
Table 3: Abbreviations for the animals age, gender and drug treatments that have been
used in this study.
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3.1 Young Male Rats
One Way ANOVA of Total ng EB/mg Protein
In the next set of figures, we presented the total ng Evans blue per protein (mg) for
the different young male groups (the control young male, the young male that have taken
R-fluoxetine and the young male that have taken the S-fluoxetine). The data was
normalized by diving the total amount of Evans blue in ng per the amount of protein
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concentration in mg that was determined by using the Bradford protein assay.

Figure 13: Young male rats that have not taken any drug (Control Young Male). The xaxis represents the different brain regions: the red color represents the cortex, the blue
color represents peri-ventricular and hippocampus, the green color represents the
striatum-caudate putamen-hypothalamus (brain), and the purple color represents the
cerebellum. The y-axis represents the total ng EB/mg protein. One-way ANOVA was
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performed. Columns represent the mean for each group and error bars show standard
error of mean (SEM). P= 0.7877. The animal number, n = 10.
Figure 13 shows that there was no significant difference between the different brain
regions (P= 0.7877). The cortex showed the lowest blood brain barrier permeability among
the different brain regions. The mean ± the standard error of the mean (SEM) for the
different brain regions are as follow: cortex: -246.7±379, peri-ventricular and
hippocampus: 6386±8309, striatum-caudate putamen-hypothalamus (brain): 2755±908.5
and the cerebellum: 4048±4099. Outliers were determined by ROUT software at medium
setting. In the hippocampus region the outlier: 80868.926 was located while 40375.985
was located in the cerebellum.

Figure 14: Young male rats that have not taken any drug (Control Young Male) without
outliers. The x-axis represents the different brain regions: the red color represents the
cortex, the blue color represents peri-ventricular and hippocampus, the green color
represents the striatum-caudate putamen-hypothalamus (brain), and the purple color
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represents the cerebellum. The y-axis represents the total ng EB/mg protein. One-way
ANOVA was performed. Columns represent the mean for each group and error bars show
standard error of mean (SEM). P= 0.0012. The n for the animal groups are as follow: the
n for the cortex =10, the n for the hippo = 9, the n for the lower brain =10 and the n for
the cerebellum =9.
Figure 14 shows that there was a significant difference between the different brain
regions (P= 0.0012). The brain region (striatum-caudate putamen-hypothalamus) showed
the highest blood brain barrier permeability among the different brain regions. The mean
± the standard error of the mean (SEM) for the different brain regions are as follow: cortex:
-246.7±379, peri-ventricular and hippocampus: -1890±825.8, striatum-caudate putamenhypothalamus (brain): 2755±908.5 and the cerebellum: 12.1±796.3.

Figure 15: Young male rats that have taken 5 mg/kg R-fluoxetine (RYM) for three days.
The x-axis represents the different brain regions: the red color represents the cortex, the
blue color represents peri-ventricular and hippocampus, the green color represents the
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striatum-caudate putamen-hypothalamus, and the purple color represents the cerebellum.
The y-axis represents the total ng EB/mg protein. One-way ANOVA was performed.
Columns represent the mean for each group and error bars show standard error of mean
(SEM). P=0.3311. The animal number, n= 11.
Figure 15 shows that there was no significant difference between the different brain
regions (P=0.3311). The mean ± the standard error of the mean (SEM) for the different
brain regions are as follow: cortex: 12308 ±12294, peri-ventricular and hippocampus: 2205±3224, striatum-caudate putamen-hypothalamus: 1397±851.6 and the cerebellum:
24093±17789. Outliers were determined by ROUT software at medium setting. In the
cerebellum the following outliers were found: 24064.006, 41496.548, and 197113.230. In
the cortex region the following outlier was found: 134723.409.

Figure 16: Young male rats that have taken 5mg/kg R-fluoxetine for three days (RYM)
without outliers. The x-axis represents the different brain regions: the red color represents
the cortex, the blue color represents peri-ventricular and hippocampus, the green color
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represents the striatum-caudate putamen-hypothalamus, and the purple color represents
the cerebellum. The y-axis represents the total ng EB/mg protein. One-way ANOVA was
performed. Columns represent the mean for each group and error bars show standard
error of mean (SEM). P=0.5943. The animal number, n for the cortex = 9, n for the hippo
= 11, n for the lower brain = 11, n for the cerebellum = 8.
Figure 16 shows that there was no significant difference between the different brain
regions (P=0.5943). The mean ± the standard error of the mean (SEM) for the different
brain regions are as follow: cortex: 66.77 ±1253, peri-ventricular and hippocampus: 2205±3224, striatum-caudate putamen-hypothalamus: 1397±851.6 and the cerebellum:
293.1±824.6.

Figure 17: Young male rats that have taken 5 mg/kg S-fluoxetine (SYM) for three days.
The x-axis represents the different brain regions: the red color represents the cortex, the
blue color represents peri-ventricular and hippocampus, the green color represents the
striatum-caudate putamen-hypothalamus, and the purple color represents the cerebellum.
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The y-axis represents the total ng EB/mg protein. One-way ANOVA was performed.
Columns represent the mean for each group and error bars show standard error of mean
(SEM). P=0.0853. The animal number, n = 7.
Figure 17 shows that there was no significant difference between the different brain
regions (P=0.0853). There is a strong trend towards a significant difference between the
permeability of the lower brain region and the cortex and hippocampus. The mean ± the
standard error of the mean (SEM) for the different brain regions are as follow: cortex: 778.2 ±1282, peri-ventricular and hippocampus: -853.8±1635, striatum-caudate putamenhypothalamus (brain): 4991±1649 and the cerebellum: 2018±2218. Outlier was determined
by ROUT software at medium setting, and it was located in the cerebellum: 15175.114.

Figure 18: Young male rats that have taken 5mg/kg S-fluoxetine for three days (SYM). The
x-axis represents the different brain regions: the red color represents the cortex, the blue
color represents peri-ventricular and hippocampus, the green color represents the
striatum-caudate putamen-hypothalamus, and the purple color represents the cerebellum.
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The y-axis represents the total ng EB/mg protein. One-way ANOVA was performed.
Columns represent the mean for each group and error bars show standard error of mean
(SEM). P= 0.0164. The n for the animal groups was as follow: the n for the cortex = 6, the
n for the hippo = 7, the n for the lower brain = 7, the n for the cerebellum = 6.
Figure 18 shows that there was a significant difference between the different brain
regions (P=0.0164). The brain region showed the highest blood brain barrier permeability
among the different brain regions. The mean ± the standard error of the mean (SEM) for
the different brain regions are as follow: cortex: -778.2 ±1282, peri-ventricular and
hippocampus: -853.8±1635, striatum-caudate putamen-hypothalamus (brain): 4991±1649
and the cerebellum: -174.7±392.8.

Figure 19: Young male rats that have taken 5mg/kg Prozac (PYM) for three days. The xaxis represents the different brain regions: the red color represents the cortex, the blue
color represents peri-ventricular and hippocampus, the green color represents the
striatum-caudate putamen-hypothalamus (brain), and the purple color represents the
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cerebellum. The y-axis represents the total ng EB/mg protein. One-way ANOVA was
performed. Columns represent the mean for each group and error bars show standard
error of mean (SEM). P= 0.1967. The animal number, n = 7.
Figure 19 shows that there was no significant difference between the different brain
regions (P= 0.1967), and the cerebellum showed the highest blood brain barrier
permeability among the different brain regions. The mean ± the standard error of the mean
(SEM) for the different brain regions are as follow: cortex: 3193±3273, peri-ventricular
and

hippocampus:

-11231±14227,

striatum-caudateputamen-hypothalamus(brain

): 3593±1440 and the cerebellum: 17815±10890.
Summary: When total ng Evans blue in regions is normalized by the amount of
protein measured from the tissue in milligrams, we see that control young males have show
a statistical difference in the permeability of Evans blue in the lower brain region compared
to the cortex, hippocampus and cerebellum, showing enhanced permeability in that region.
S-fluoxetine did produce increased permeability (statistically different) in the lower brain
region, while R-fluoxetine tightened the BBB permeability in this region, removing
statistical differences in BBB permeability between the regions. Prozac, which is a mixture
of R- and S-fluoxetine, did not show any significant differences in permeability between
the brain regions tested.
3.2 Old Male Rats
One Way ANOVA total ng EB/mg protein
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In the next set of figures, we normalized the amount of Evans blue in a region by
dividing the total ng Evans blue in that region by the protein concentration in mg,
determined by a Bradford protein assay for the old male rats.

Figure 20: Old male rats that have not taken any drug (COM). The x-axis represents the
different brain regions: the red color represents the cortex, the blue color represents periventricular and hippocampus, the green color represents the striatum-caudate putamenhypothalamus (brain), and the purple color represents the cerebellum. The y-axis
represents the total ng EB/mg protein. One-way ANOVA was performed. Columns
represent the mean for each group and error bars show standard error of mean (SEM).
P= 0.0074. The animal number, n = 7.
Figure 20 shows that there was a significant difference between the different brain
regions (P= 0.0074), and the hippocampus region showed the lowest blood brain barrier
permeability among the different brain regions. The mean ± the standard error of the mean
for the different brain regions are as follow: cortex: 347.2±188.8, peri-ventricular and
44

hippocampus: -771.1±317.7, striatum-caudate putamen-hypothalamus (brain): 263±179.6
and the cerebellum: 140.8±207.

Figure 21: Old male rats that given 5 mg/kg S-fluoxetine (SOM) for three days. The x-axis
represents the different brain regions: the red color represents the cortex, the blue color
represents peri-ventricular and hippocampus, the green color represents the striatumcaudate putamen-hypothalamus (brain), and the purple color represents the cerebellum.
The y-axis represents the total ng EB. One-way ANOVA was performed. Columns represent
the mean for each group and error bars show standard error of mean (SEM). P= 0.2667.
The animal number, n = 7.
Figure 21 shows that there was no significant difference between the different brain
regions (P=0.2667). The hippocampus showed the lowest blood brain barrier permeability.
The mean ± the standard error of the mean for the different brain regions are as follow:
cortex: 194.2 ±135.1, peri-ventricular and hippocampus: -3411±3191, striatum-caudate
putamen-hypothalamus (brain): 820±603.6 and the cerebellum: 4306.474579. Outliers
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were determined by ROUT software at medium setting. The outlier: 22521.990 was located
in the hippocampus region. The outlier: 4306.475 was located in the brain region.

Figure 22: Old male rats that given 5 mg/kg S-fluoxetine (SOM) for three days without
outliers. The x-axis represents the different brain regions: the red color represents the
cortex, the blue color represents peri-ventricular and hippocampus, the green color
represents the striatum-caudate putamen-hypothalamus (brain), and the purple color
represents the cerebellum. The y-axis represents the total ng EB. One-way ANOVA was
performed. Columns represent the mean for each group and error bars show standard
error of mean (SEM). P= 0.2553. The n for the animal numbers are as follow: the n for the
cortex = 7, the n for the hippo = 6, the n for the lower brain = 6, the n for the cerebellum
= 7.
Figure 22 shows that there was no significant difference between the different brain
regions (P=0.2553). The mean ± the standard error of the mean for the different brain
regions are as follow: cortex: 194.2 ±135.1, peri-ventricular and hippocampus: 46

226.3±237.1, striatum-caudate putamen-hypothalamus (brain): 238.9±193.4 and the
cerebellum: 161.2±127.9.

Figure 23: Old male rats that have taken 5 mg/kg R-fluoxetine (ROM) for three days. The
x-axis represents the different brain regions: the red color represents the cortex, the blue
color represents peri-ventricular and hippocampus, the green color represents the
striatum-caudate putamen-hypothalamus (brain), and the purple color represents the
cerebellum. The y-axis represents the total ng EB/mg protein. One-way ANOVA was
performed. Columns represent the mean for each group and error bars show standard
error of mean (SEM). P= 0.0221. The animal number, n = 7.
Figure 23 shows that there was a significant difference between the different brain
regions (P= 0.0221), and the hippocampus showed the lowest blood brain barrier
permeability among the different brain regions. The mean ± the standard error of the mean
for the different brain regions are as follow: cortex: 326.1±180.3, peri-ventricular and
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hippocampus: -902±267, striatum-caudate putamen-hypothalamus (brain): -72.23±565.1
and the cerebellum: 671.2±231.
Summary: When total ng Evans blue in regions is normalized by the amount of
protein measured from the tissue in milligrams, we see that there is a significant difference
in the blood brain barrier regions among the old male rats that have not taken any medicine
and the old male rats that have taken 5mg/kg of R-fluoxetine, with the hippocampus
showing statistically lower permeability compared to the other brain regions. The old male
rats that have taken 5mg/kg of S-fluoxetine did not show any significant difference in the
blood brain barrier permeability.
3.3 Old Female Rats
One Way ANOVA total ng EB/mg protein
The following figures represent the one-way ANOVA for the different female rats
(control female rats, the female rats that have taken R-fluoxetine, and the female rats that
have taken S-fluoxetine). The figures represent the normalized measurements of Evans
blue in the different brain regions of the female rats. The Evans blue was normalized by
measuring the total amount of Evans blue per the protein concentration (mg). The protein
was measured by using the Bradford protein assay.

48

Figure 24: Old female rats that have not taken any drug (COF). The x-axis represents the
different brain regions: the red color represents the cortex, the blue color represents periventricular and hippocampus, the green color represents the striatum-caudate putamenhypothalamus (brain), and the purple color represents the cerebellum. The y-axis
represents the total ng EB/mg protein. One-way ANOVA was performed. Columns
represent the mean for each group and error bars show standard error of mean (SEM).
P= 0.0601. The animal number, n = 7.
Figure 24 shows that there was a strong trend for a significant difference between
the different brain regions (P= 0.0601). The hippocampus showed the lowest blood brain
barrier permeability among the different brain regions. The mean for the different brain
regions are as follow: cortex: -540.4±675.7, peri-ventricular and hippocampus: 2376±1649, striatum-caudate putamen-hypothalamus (brain): 455.9±139.6 and the
cerebellum: 1172±393.9. Outliers were determined by ROUT software at medium setting.
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The outlier -4503.975 was located in the cortex while the outlier -12021.576 was located
in the hippocampus.

Figure 25: Old female rats that have not taken any drug (COF). The x-axis represents the
different brain regions: the red color represents the cortex, the blue color represents periventricular and hippocampus, the green color represents the striatum-caudate putamenhypothalamus (brain), and the purple color represents the cerebellum. The y-axis
represents the total ng EB/mg protein. One-way ANOVA was performed. Columns
represent the mean for each group and error bars show standard error of mean (SEM).
P= 0.0023. The animal numbers, n for the different brain regions are as follow: the n for
cortex = 6, the n for the hippo = 6, the n for the lower brain = 7, the n for the cerebellum
= 7.
Figure 25 shows that there was a significant difference between the different brain
regions (P= 0.0023), with the cerebellum showing enhanced permeability compared to the
other brain regions. The mean ± the standard error of the mean for the different brain
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regions are as follow: cortex: 120.2±168.3, peri-ventricular and hippocampus: -768±434.8,
striatum-caudate putamen-hypothalamus (brain): 455.9±139.6 and the cerebellum:
1172±393.9.

Figure 26: Old female rats that have taken 5 mg/kg S-fluoxetine (SOF) for three days. The
x-axis represents the different brain regions: the red color represents the cortex, the blue
color represents peri-ventricular and hippocampus, the green color represents the
striatum-caudate putamen-hypothalamus, and the purple color represents the cerebellum.
The y-axis represents the total ng EB/mg protein. One-way ANOVA was performed.
Columns represent the mean for each group and error bars show standard error of mean
(SEM). P= 0.0136. The animal number, n = 6.
Figure 26 shows that there was a significant difference between the different brain
regions (P= 0.0136). The hippocampus showed the lowest blood brain barrier permeability
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among the different brain regions, and the cerebellum showed the highest permeability.
The mean ± the standard error of the mean for the different brain regions are as follow:
cortex: 509.7±252.4, peri-ventricular and hippocampus: -4622±2673, striatum-caudate
putamen-hypothalamus (brain): 29.63±250.6 and the cerebellum: 3232±1428.

Figure 27: Old female rats that have taken 5 mg/kg R-fluoxetine (ROF) for three days. The
x-axis represents the different brain regions: the red color represents the cortex, the blue
color represents peri-ventricular and hippocampus, the green color represents the
striatum-caudate putamen-hypothalamus (brain), and the purple color represents the
cerebellum. The y-axis represents the total ng EB/mg protein. One-way ANOVA was
performed. Columns represent the mean for each group and error bars show standard
error of mean (SEM). P= 0.1956. The animal number, n = 7.
Figure 27 shows that there was no significant difference between the different brain
regions (P=0.1956). The hippocampus showed the lowest blood brain barrier permeability
among the different brain region. The mean ± the standard error of the mean for the
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different brain regions are as follow: cortex: -856.5±1463, peri-ventricular and
hippocampus:

-2369±847.8,

striatum-caudate

putamen-hypothalamus

(brain):

-

207.1±250.5 and the cerebellum: 240.8±390.3. The outlier was determined by using ROUT
analysis at medium setting. It was located at the cortex region. The outlier was -9420.832.

Figure 28: Old female rats that have taken 5 mg/kg R-fluoxetine (ROF) for three days
without outliers. The x-axis represents the different brain regions: the red color represents
the cortex, the blue color represents peri-ventricular and hippocampus, the green color
represents the striatum-caudate putamen-hypothalamus (brain), and the purple color
represents the cerebellum. The y-axis represents the total ng EB/mg protein. One-way
ANOVA was performed. Columns represent the mean for each group and error bars show
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standard error of mean (SEM). P= 0.0028. The animal number, n for the cortex = 6, n for
hippo = 7, n for the lower brain = 7, n for the cerebellum = 7.
Figure 28 shows that there was significant difference between the different brain
regions (P=0.0028), with the hippocampus showing statistically lower permeability. The
mean ± the standard error of the mean for the different brain regions are as follow: cortex:
570.8±380.8, peri-ventricular and hippocampus: -2369±847.8, striatum-caudate putamenhypothalamus (brain): -207.1±250.5 and the cerebellum: 240.8±390.3.
Summary: Total ng Evans blue in regions was normalized by the amount of protein
measured from the tissue in milligrams. Our statistical analysis showed that there was a
significant difference in the blood brain barrier permeability in the different brain regions
with the hippocampus showing the lowest blood brain barrier permeability and the
cerebellum showing higher blood brain barrier permeability in both control and Sfluoxetine groups.
3.4. Young Male Rats versus Old Male Rats
Two-Way ANOVA of total ng EB/mg Protein
The following set of figures represents the two-way ANOVA of the comparison
between the different groups of the old males and the young males. The measurements of
Evans blue were normalized by measuring the total amount of Evans blue in ng and then
dividing it by the amount of protein concentration in mg. The Bradford protein assay was
used to measure the amount of the protein concentration.
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Figure 29: Comparison between young male and old male rats that have given 5 mg/kg Rfluoxetine (RYM vs. ROM) for three days. The x-axis represents the different brain regions:
cortex, peri-ventricular and hippocampus, striatum-caudate putamen-hypothalamus
(brain), cerebellum. The y-axis represents the total ng EB/mg protein. Two-way ANOVA
was performed. Columns represent the mean for each group and error bars show standard
error of mean (SEM). Interaction, P=0.5811. Region, P=0.4934. Age, P=0.2044. The
number of the animals, n was as follow: the n for the ROM =7, the n for the RYM =11.
Figure 29 shows that there was no significant difference for interaction between the
different brain regions and age groups (P = 0.5811). Also, there was no significant
difference between the different brain regions between the groups (P = 0.4934). In addition,
there was no significant difference between the young and the old males (P =0.2044). The
root mean square error, which is defined as the residual mean square. It is used to estimates
the common within-group standard deviation which also known as the standard error of
the estimate were as the following. The mean ± the standard error of the mean for ROM:
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5.78±338.6, RYM: 8898±5930. The mean ± the standard error of the mean: ROM: 5.787
± 4783.159, RYM: 8410.804 ± 4079.092. The mean ± the standard error of the mean for
the different brain regions are as follow: cortex: 6317.183 ± 6541.099, hippo: -2528.268 ±
6541.099, brain: 662.374 ± 6541.099, cerebellum: 12381.893 ± 5450.916.

Figure 30: Comparison between old male rats that have given R-fluoxetine for three days,
and young male rats that R-fluoxetine (ROM vs. RYM). The x-axis represents the different
brain regions: cortex, peri-ventricular and hippocampus, striatum-caudate putamenhypothalamus (brain), and cerebellum. The y-axis represents the total ng EB. Two-way
ANOVA was performed. Columns represent the mean for each group and error bars show
standard error of mean (SEM). Interaction, P=0.820. Region, P=0.466. Age, P=0.916.
The n for the animal numbers was as follow: the n for the ROM = 7, the n for the animal
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groups of the RYM was as follow: the n for the cortex was 9, the n for the hippo was 11,
the n for the brain was 11 and the n for the cerebellum was 8.
Figure 30 shows that there was no significant difference for interaction between the
different brain regions and age groups (P = 0.820). Also, there was no significant difference
between the different brain regions between the groups (P = 0.466). In addition, there was
no significant difference between the young and the old males (P =0.916). The root mean
square error, which is defined as the residual mean square. It is used to estimates the
common within-group standard deviation which also known as the standard error of the
estimate were as the following. The mean ± the standard error of the mean for the different
brain regions are as follow: cortex: 196.441 ±1133.443, peri-ventricular and hippocampus:1553.296 ±1112.027, striatum-caudate putamen-hypothalamus (brain): 662.367±
998.075and the cerebellum: 482.149 ±1190.354. The mean ± the standard error of the mean
for the treatment groups was as follow: RYM: -111.950 ±691.300, ROM: 5.780 ±869.311.

Figure 31: Comparison between young male and old male rats that have given 5 mg/kg S57

fluoxetine (SYM vs. SOM) for three days. The x-axis represents the different brain regions:
cortex, peri-ventricular and hippocampus, striatum-caudate putamen-hypothalamus
(brain), cerebellum. The y-axis represents the total ng EB/mg protein. Two-way ANOVA
was performed. Columns represent the mean for each group and error bars show standard
error of mean (SEM). Interaction, P=0.5558. Region, P=0.0342. Age, P=0.1354. The
animal numbers, n for the different animal groups were as follow, the n for the SOM =7,
the n for the SYM =7.
Figure 31 shows that there was no significant difference for interaction between the
different brain regions and age groups (P = 0.5558). Also, there was a significant difference
between the different brain regions between the groups (P = 0.0342). In addition, there was
no significant difference between the young and the old males (P =0.1354). The root mean
square error, which is defined as the residual mean square. It is used to estimates the
common within-group standard deviation which also known as the standard error of the
estimate were as the following. The mean ± the standard error of the mean for SOM: 559.023 ± 806.390, SYM: 534.440 ± 823.019. The mean ± the standard error of the mean
for the different brain regions: cortex: -292.006 ± 1186.974, hippo: -1888.090 ± 1140.408,
brain: 1041.251 ± 1140.408, cerebellum: 1089.678 ± 1140.408.
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Figure 32: Comparison between old male rats that have given S-fluoxetine, and young
male rats that have given S-fluoxetine (SOM vs. SYM) for three days without outliers. The
x-axis represents the different brain regions: cortex, peri-ventricular and hippocampus,
striatum-caudate putamen-hypothalamus (brain), and cerebellum. The y-axis represents
the total ng EB. Two-way ANOVA was performed. Columns represent the mean for each
group and error bars show standard error of mean (SEM). Interaction, P= 0.599. Region,
P= 0.446. Age, P= 0.850. The animal numbers, n for the SOM of the cortex was 7, the
hippocampus was 6, the brain was 6 and the cerebellum was 7. The n for the SYM was as
follow: the n for the cortex was 6, the n for the hippo was 7, the n for the brain was 7, and
the n for the cerebellum was 6.
Figure 32 shows that there was no significant difference for interaction between the
different brain regions and age groups (P = 0.599). Also, there was no significant difference
between the different brain regions between the groups (P = 0.446). In addition, there was
no significant difference between the young and the old males (P =0.850). The root mean
square error, which is defined as the residual mean square. It is used to estimates the
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common within-group standard deviation which also known as the standard error of the
estimate were as the following. The mean ± the standard error of the mean for SOM:
91.98±107.3, SYM: 796.1±1407. The mean ± the standard error of the mean for the
different brain regions: cortex: -292.006 ± 576.364, hippo: -295.543 ± 576.364, brain:
750.708 ± 492.705, cerebellum: -6.736 ± 576.364.

Figure 33: Comparison between young male and old male rats that have not given any
drug (CYM vs. COM). The x-axis represents the different brain regions: cortex, periventricular

and

hippocampus,

striatum-caudate

putamen-hypothalamus

(brain),

cerebellum. The y-axis represents the total ng EB/mg protein. Two-way ANOVA was
performed. Columns represent the mean for each group and error bars show standard
error of mean (SEM). Interaction, P=0.8059. Region, P=0.9141. Age, P=0.2539. The

60

animal numbers, n for the different animal groups were as follow, the n for the COM =7,
the n for the CYM =10.
Figure 33 shows that there was no significant difference for interaction between the
different brain regions and age groups (P = 0.8059). Also, there was no significant
difference between the different brain regions between the groups (P = 0.9141). In addition,
there was no significant difference between the young and the old males (P =0.2539). The
root mean square error, which is defined as the residual mean square. It is used to estimates
the common within-group standard deviation which also known as the standard error of
the estimate were as the following. The mean± the standard error of the mean for COM:
-5.023±258.9, SYM: 3236±1383. The mean ± the standard error of the mean was as follow:
COM -5.023 ± 2157.676, CYM: 3235.603 ± 1805.242. The mean ± the standard error of
the mean for the different brain regions was as follow: cortex: 50.286 ±, hippo: 2807.251,
brain: 1508.976, cerebellum: 2094.647.
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Figure 34: Comparison between old male rats that have not taken a drug (COM), and
young male rats that have not taken a drug (CYM). The x-axis represents the different brain
regions: cortex, peri-ventricular and hippocampus, striatum-caudate putamenhypothalamus (brain), and cerebellum. The y-axis represents the total ng EB. Two-way
ANOVA was performed. Columns represent the mean for each group and error bars show
standard error of mean (SEM). Interaction, P=0.030. Region, P<0.001. Age, P=0.736.
The animal numbers, n for the different animal groups were as follow: the n for the COM
=7, the n for the CYM for the different brain regions were as follow: the n for the cortex
was 10, the n for the hippocampus was 9, the n for the brain is 10 and n for the cerebellum
was 9.

Figure 34 shows that there was significant difference for interaction between the different
brain regions and age groups (P = 0.030). Also, there was significant difference between
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the different brain regions between the groups (P < 0.001). In addition, there was no
significant difference between the young and the old males (P =0.736). The root mean
square error, which is defined as the residual mean square. It is used to estimates the
common within-group standard deviation which also known as the standard error of the
estimate were as the following. The mean ± the standard error of the mean for the different
brain regions are as follow: cortex: 50.288 ± 486.556, peri-ventricular and hippocampus: 1330.710 ± 497.562, striatum-caudate putamen-hypothalamus (brain): 1508.976 ± 433.586
and the cerebellum: 76.453 ± 497.562. The mean ± the standard error of the mean for the
treatment groups was as follow: CYM: 157.526 ± 301.182, COM: -5.023 ± 373.171.
Summary: Total ng Evans blue in regions was normalized by the amount of protein
measured from the tissue in milligrams. We compared the amount of total ng Evans blue
among the different groups (control, S-fluoxetine and R-fluoxetine) between the young and
the old males. The R-fluoxetine groups showed no significant difference in interaction,
region nor age. The S-fluoxetine showed a significant difference in interaction and region.
The young males in the S-fluoxetine showed the highest blood brain barrier permeability
in the lower brain regions among the different brain regions in the brain. The S-fluoxetine
has increased the blood brain barrier permeability in the brain region. The control group
showed a significant interaction in the interaction and the region. In the control group, the
brain showed the highest blood brain barrier permeability among the different brain
regions.
3.5 Comparison among the Young Males Groups
Two Way ANOVA of total ng EB/mg Protein
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In the figures that are listed below, we compared the total ng Evans Blue per mg of
protein for the different groups of the young males. We normalized the data by diving the
total ng of Evans blue by the protein concertation (mg) which was measured by Bradford
protein assay.

Figure 35: Comparison between young male rats that have given 5 mg/kg S-fluoxetine for
three days, and young male rats that have not given any drug (SYM vs. CYM). The x-axis
represents the different brain regions: cortex, peri-ventricular and hippocampus, striatumcaudate putamen-hypothalamus (brain), cerebellum. The y-axis represents the total ng
Evans Blue/mg protein. Two-way ANOVA was performed. Columns represent the mean for
each group and error bars show standard error of mean (SEM). Interaction, P= 0.7098.
Region, P =0.7486. Treatment, P= 0.5249. The n for the different animal groups were as
follow: the n for the CYM =10, the n for the SYM =7.
Figure 35 shows that there was no significant difference in ng Evans Blue/mg protein in
young male rats for interaction between the different brain regions and the drug treatment
groups (P = 0.7098). Also, there was no significant difference between the different brain
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regions between the groups (P =0.7486). In addition, there was no significant difference
between the different drug treatment groups (P =0.5249). ROUT analysis at medium
setting was used to find out the outliers. The SYM had an outlier (15175.114) at the
cerebellum region of the brain. The CYM had two outliers. The first outlier (80868.926)
was located at the hippocampus region while the second outlier (40375.985) was located
at the cerebellum region. The root mean square error, which is defined as the residual mean
square. It is used to estimates the common within-group standard deviation which also
known as the standard error of the estimate were as the following. The mean ± the standard
error of the mean: CYM: 3235.604 ± 1874.775, SYM: 1344.297 ± 2286.992. The mean ±
the standard error of the mean for the different brain regions was as follow: Cortex: 512.418 ± 3061.495, hippo: 2765.933 ± 2921.626, brain: 3872.970 ± 2921.626,
cerebellum: 3033.315 ± 2921.626.

Figure 36: Comparison between young male rats that have given 5 mg/kg S-fluoxetine for
three days, and young male rats that have not given any drug (SYM vs. CYM). The x-axis
represents the different brain regions: cortex, peri-ventricular and hippocampus, striatum-
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caudate putamen-hypothalamus (brain), cerebellum. The y-axis represents the total ng
EB/mg protein. Two-way ANOVA was performed. Columns represent the mean for each
group and error bars show standard error of mean (SEM). Interaction, P= 0.5247. Region,
P <0.0001. Treatment, P= 0.3874. The n for the animal groups of the CYM was as follow:
the n for the cortex was 10, the n for the hippocampus was 9, the n for the brain was 10 and
the n for the cerebellum was 9. The n for the SYM was as follow: the n for the cortex was
6, the n for the hippocampus was 7, the n for the brain was 7, and the n for the cerebellum
6.
Figure 36 shows data from Figure 35 that has removed the statistical outliers. This data
indicates there was no significant difference in ng Evans Blue/mg protein for the interaction
between the different brain regions and the drug treatment groups (P = 0.5247). However,
there was a significant difference in ng Evans Blue/mg protein between the different brain
regions for the young male (P < 0.0001), with the lower brain region showing a higher
permeability. There was no significant difference between the different drug treatment
groups (P =0.3874; control versus S-fluoxetine) in the young male rats. The root mean
square error, which is defined as the residual mean square. It is used to estimates the
common within-group standard deviation which also known as the standard error of the
estimate were as the following. The mean ± the standard error of the mean for CYM:
157.526 ± 466.809, SYM: 796.089 ± 565.238. The mean ± the standard error of the mean
for the different brain regions are as follow: cortex: -512.418 ± 741.965, hippo: -1372.028
± 724.084, brain: 3872.970 ± 708.067, cerebellum: -81.294 ± 757.265.
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Figure 37: Comparison between young male rats that have given 5 mg/kg R-fluoxetine for
three days, and young male rats that have not given any drug (RYM vs. CYM). The x-axis
represents the different brain regions: cortex, peri-ventricular and hippocampus, striatumcaudate putamen-hypothalamus (brain), cerebellum. The y-axis represents the total ng
EB/mg protein. Two-way ANOVA was performed. Columns represent the mean for each
group and error bars show standard error of mean (SEM). Interaction, P= 0.939. Region,
P= 0.062. Treatment, P = 0.804. The animal numbers (n) for the different animal groups
were as follow: the n for the CYM =10, the n for the RYM =11.
Figure 37 shows there was no significant difference in ng Evans Blue/ mg protein for the
interaction between the different brain regions and the drug treatment groups (P = 0.939;
control versus R-fluoxetine). Also, there was no significant difference between the
different brain regions for the young male rats (P = 0.062). In addition, there was no
significant difference between the drug treatment groups (P =0.804; control versus Rfluoxetine). The statistical outliers were determined by using the ROUT analysis at
medium setting. The CYM had two outliers. The first outlier (80868.926) was located at
the hippocampus region while the second outlier (40375.985) was located at the cerebellum
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region. The RYM group had four outliers. The first outlier (134723.409) was located at the
cortex. In contrast, the rest of the outliers (24064.006, 41496.548 and 197113.231) were
located at the cerebellum. The root mean square error, which is defined as the residual
mean square. It is used to estimates the common within-group standard deviation which
also known as the standard error of the estimate were as the following. The mean ± the
standard error of the mean: CYM: 3235.604 ± 4171.233, RYM: 8898.305 ± 3720.250. The
mean ± the standard error of the mean for the brain regions was as follow: cortex: 6060.813
± 5763.387, hippo: 2090.514 ± 5763.387, brain: 2075.962 ± 5030.697, Cere: 14070.529 ±
5763.387.

Figure 38: Comparison between young male rats that have given 5 mg/kg R-fluoxetine for
three days, and young male rats that have not given any drug (RYM vs. CYM). The x-axis
represents the different brain regions: cortex, peri-ventricular and hippocampus, striatumcaudate putamen-hypothalamus (brain), cerebellum. The y-axis represents the total ng
EB/mg protein. Two-way ANOVA was performed. Columns represent the mean for each
group and error bars show standard error of mean (SEM). Interaction, P= 0.9388. Region,
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P= 0.0620. Treatment, P = 0.8042. The n for the animal numbers for the different animal
groups were as follow: the n for the CYM for the different brain regions were as follow:
the n for the cortex was 10, the n for the hippocampus was 9, the n for the brain was 10 and
the n for the cerebellum was 9. The n for the RYM was as follow: the n for the cortex was
9, the n for the hippocampus was 11, the n for the brain was 11 and the n for the cerebellum
was 8.
Figure 38 shows the data from Figure 37 with the statistical outlier removed. The data
indicates there was no significant difference in the ng Evans Blue/mg protein for interaction
between the different brain regions and the drug treatment groups (P = 0.9388; control
versus R-fluoxetine). Also, there was no significant difference between the different brain
regions between the groups (P = 0.0620), but the P value does indicate a very strong trend
here. In addition, there was no significant difference between the treatment groups (P
=0.8042). The root mean square error, which is defined as the residual mean square. It is
used to estimates the common within-group standard deviation which also known as the
standard error of the estimate were as the following. The mean ± the standard error of the
mean for the different brain regions are as follow: cortex: -89.943±1063.861, periventricular

and

hippocampus:-2047.447

±1069.221,

striatum-caudate

putamen-

hypothalamus (brain): 2075.962 ±1039.401 and the cerebellum: 152.580 ±1155.921. The
mean ± the standard error of the mean for the treatment groups was as follow: CYM:
157.526 ± 772.877, RYM: -111.950 ± 758.648.
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Figure 39: Comparison between young male rats that have given 5 mg/kg R-fluoxetine for
three days, and young male rats that have given 5 mg/kg of S-fluoxetine (RYM vs. SYM).
The x-axis represents the different brain regions: cortex, peri-ventricular and
hippocampus, striatum-caudate putamen-hypothalamus (brain), cerebellum. The y-axis
represents the total ng EB/mg protein. Two-way ANOVA was performed. Columns
represent the mean for each group and error bars show standard error of mean (SEM).
Interaction, P= 0.5279. Region, P= 0.5251. Treatment, P = 0.2921. The n for the animal
numbers of the different animal groups were as follow: the n for the RYM =11, the n for
the SYM =7.
Figure 39 shows that the data indicates that there was no significant difference in
the ng Evans blue/ mg protein for interaction between the different brain regions and drug
treatment groups (p= 0.5279; R-fluoxetine vs. S-fluoxetine treatment group). Also, there
was no significant difference between the different brain regions between the groups (P =
0.5251). In addition, there was no significant difference between the treatment groups (P
=0.2921). The ROUT analysis at medium setting was used to determine the outliers. The
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SYM had an outlier at the cerebellum. The outlier was 15175.114. The RYM had four
outliers. The first outlier was 134723.409. It was found at the cortex. The other outliers
were found at the cerebellum. These outliers include: 24064.006, 41496.548, and
197113.231. The root mean square error, which is defined as the residual mean square. It
is used to estimates the common within-group standard deviation which also known as the
standard error of the estimate were as the following. The mean ± the standard error of the
mean, RYM: 8898.305 ± 4378.361, SYM: 1344.297 ± 5601.744. The mean ± the standard
error of the mean for the different brain regions: cortex: 5765.054 ± 7369.880, hippo: 1529.182 ± 7020.997, brain: 3193.973 ± 7020.997, cerebellum: 13055.360 ± 7020.997.

Figure 40: Comparison between young male rats that have given 5 mg/kg R-fluoxetine for
three days, and young male rats that have given 5 mg/kg of S-fluoxetine (RYM vs. SYM).
The x-axis represents the different brain regions: cortex, peri-ventricular and
hippocampus, striatum-caudate putamen-hypothalamus (brain), cerebellum. The y-axis
represents the total ng EB/mg protein. Two-way ANOVA was performed. Columns
represent the mean for each group and error bars show standard error of mean (SEM).
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Interaction, P= 0.6384. Region, P= 0.0787. Treatment, P = 0.5082. The n for the animal
numbers of the different animal groups were as follow: the n for the RYM for the different
brain regions were as follow: the n for the cortex was 9. The n for the hippocampus was
11, the n for the brain was 11 and the n for the cerebellum was 8, the n for the SYM was as
follow: the n for the cortex was 6, the n for the hippocampus was 7, the n for the brain was
7, and the n for the cerebellum was 6.

Figure 40 shows the data from Figure 39, but with the statistical outliers removed.
The data shows there was no significant difference in ng Evans Blue/mg protein for the
interaction between the different brain regions and the drug treatment groups (P = 0.6384;
R-fluoxetine versus S-fluoxetine). Also, there was no significant difference between the
different brain regions between the groups (P = 0.0787), but the P value does show a very
strong trend here. In addition, there was no significant difference between the treatment
groups (P =0.5082). The root mean square error, which is defined as the residual mean
square. It is used to estimates the common within-group standard deviation which also
known as the standard error of the estimate were as the following. The mean ± the standard
error of the mean: RYM: -111.950 ± 901.296, SYM: 1344.297 ± 1090.216. The mean ±
the standard error of the mean: cortex: -355.702 ± 1459.425, hippo: -1529.182 ± 1366.432,
brain: 3193.973 ± 1366.432, cerebellum: 1155.606 ± 1462.679.
Summary: Total ng Evans blue in regions was normalized by the amount of protein
measured from the tissue in milligrams. Our analysis showed that there were no significant
difference in the interaction, region and treatment in the comparison between the CYM
versus RYM. Also, there were no significant difference in the interaction, region and
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treatment in the comparison between RYM versus SYM. There was a significant difference
in the region for the SYM group in the comparison of CYM versus SYM.
5 mg/kg Prozac young male versus different treatment groups among young males

Figure 41: Comparison between young male rats that have given 5 mg/kg S-fluoxetine,
and young male rats that have given 5 mg/kg Prozac (SYM vs. PYM) for three days. The xaxis represents the different brain regions: cortex, peri-ventricular and hippocampus,
striatum-caudate putamen-hypothalamus (brain), cerebellum. The y-axis represents the
total ng EB/mg protein. Two-way ANOVA was performed. Columns represent the mean for
each group and error bars show standard error of mean (SEM). Interaction, P=0.2677.
Region, P=0.1259. Treatment, P=0.6755. The n for the animal groups was as follow:
SYM=7, PYM=7.
Figure 41 shows there was no significant difference in ng Evans Blue/mg protein for
interaction between the different brain regions and the drug treatment groups (P = 0.2677;
S-fluoxetine versus Prozac). Also, there was no significant difference between the different
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brain regions between the groups (P = 0.1259). In addition, there was no significant
difference the drug treatment groups (P =0.6755Outlier was determined by using the
ROUT analysis at medium settings. The outlier was located at the SYM group at the
cerebellum (15175.114). The root mean square error, which is defined as the residual mean
square. It is used to estimates the common within-group standard deviation which also
known as the standard error of the estimate were as the following. The mean ± the standard
error of the mean for the SYM: 1344.297 ± 2976.671, PYM: 3342.441 ± 3109.031. The
mean ± the standard error of the mean for the different brain regions was as follow: the
cortex: 1207.318 ± 4576.370, the hippo: -6042.555 ± 4396.834, the brain: 4292.009 ±
3807.770, the cerebellum: 9916.704 ± 4396.834.

Figure 42: Comparison between young male rats that have given 5 mg/kg S-fluoxetine,
and young male rats that have given 5 mg/kg of Prozac (SYM vs. PYM) for three days. The
x-axis represents the different brain regions: cortex, peri-ventricular and hippocampus,
striatum-caudate putamen-hypothalamus, and cerebellum. The y-axis represents the total
ng EB/mg protein. Two-way ANOVA was performed. Columns represent the mean for each
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group and error bars show standard error of mean (SEM). Interaction, P=0.175. Region,
P=0.289. Treatment, P=0.046. The n for the animal groups of the SYM was as follow: the
n for the cortex was 6, the n for the hippocampus was 7, the n for the brain was 7, the n for
the cerebellum was 6. The n for the PYM = 7.
Figure 42 shows the data from Figure 41 with the statistical outliers removed. The data
shows that there was no significant difference in ng Evans Blue/mg protein for the
interaction between the different brain regions and the drug treatment (P = 0.175; Sfluoxetine versus Prozac). Also, there was no significant difference between the different
brain regions in the young male rats (P = 0. 289). In addition, there was a significant
difference between the drug treatments (P =0.046; S-Fluoxetine versus Prozac). The root
mean square error, which is defined as the residual mean square. It is used to estimates the
common within-group standard deviation which also known as the standard error of the
estimate were as the following. The mean ± the standard error of the mean for the different
brain regions are as follow: cortex: 1207.318 ± 3150.173, peri-ventricular and
hippocampus: 1369.637 ± 3026.589, striatum-caudate putamen-hypothalamus (brain):
4149.152 ± 3026.589 and the cerebellum: 8820.290 ± 3150.173. The mean ± the standard
error of the mean for the treatment groups was as follow: SYM: 724.661± 2227.509, PYM:
7048.537 ± 2140.121.
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Figure 43: Comparison between young male rats that have given 5 mg/kg R-fluoxetine,
and young male rats that have given 5 mg/kg Prozac (RYM vs. PYM) for three days. The
x-axis represents the different brain regions: cortex, peri-ventricular and hippocampus,
striatum-caudate putamen-hypothalamus (brain), cerebellum. The y-axis represents the
total ng Evans Blue/mg protein. Two-way ANOVA was performed. Columns represent the
mean for each group and error bars show standard error of mean (SEM). Interaction,
P=0.947, Region, P=0.066, Treatment, P=0.465. The n for the different animal groups
was as follow, RYM=11, PYM =7 .
Figure 43 shows there was no significant difference in ng Evans Blue/mg protein for the
interaction between the different brain regions and drug treatment groups (P = 0.947; Rfluoxetine versus Prozac). Also, there was no significant difference between the different
brain regions between the groups (P = 0.066), although this P value does show a strong
trend. In addition, there was no significant difference between the different drug treatment
groups (P =0.465; R-fluoxetine versus Prozac). The outliers were determined by using the
ROUT analysis at medium setting. The RYM group had four outliers. The first outlier
(134723.409) was located at the cortex. In contrast, the rest outliers (24064.006, 41496.548
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and 197113.231) were located at the cerebellum. The root mean square error, which is
defined as the residual mean square. It is used to estimates the common within-group
standard deviation which also known as the standard error of the estimate were as the
following. The mean ± the standard error of the mean: RYM: 8898.305 ± 4905.524, PYM:
3342.441 ± 5752.236. The mean ± the standard error of the mean for the different brain
regions was as follow: cortex: 7750.548 ± 7866.338, hippo: -6717.974 ± 6555.282, brain:
2495.001 ± 7866.338, cerebellum: 20953.918 ± 7866.338. The mean ± the standard error
of the mean: RYM: 8898.305 ± 4905.524, PYM: 3342.441 ± 5752.236. The mean ± the
standard error of the mean for the different brain regions are as follow: cortex: 7750.548 ±
7866.338, hippo: -6717.974 ± 6555.282, brain: 2495.001 ± 7866.338, cerebellum:
20953.918 ± 7866.338.

Figure 44: Comparison between young male rats that have given 5 mg/kg R-fluoxetine,
and young male rats that have taken 5mg/kg of Prozac (RYM vs. PYM) for three days. The
x-axis represents the different brain regions: cortex, peri-ventricular and hippocampus,
striatum-caudate putamen-hypothalamus, and cerebellum. The y-axis represents the total
ng EB/mg protein. Two-way ANOVA was performed. Columns represent the mean for each
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group and error bars show standard error of mean (SEM). Interaction, P= 0.152, Region,
P=0.059, Treatment, P= 0.387. The n of the animal groups of the RYM were as follow: the
n for the cortex was 9, the n for the hippo was 11, the n for the brain was 11 and the n for
the cerebellum was 8. The n for the PYM =7.

Figure 44 shows the data from Figure 43 without the statistical outliers. The data shows
that there was no significant difference in ng Evans Blue/mg protein for the interaction
between the different brain regions and drug treatments (P = 0.152; R-fluoxetine versus
Prozac) although the P value is low and does show a trend. Also, there was no significant
difference between the different brain regions in the young male rats (P = 0. 059), with this
P value just missing significance, showing a very strong trend. In addition, there was no
significant difference between the drug treatments (P =0.387; R-fluoxetine versus Prozac).
The root mean square error, which is defined as the residual mean square. It is used to
estimates the common within-group standard deviation which also known as the standard
error of the estimate were as the following. The mean ± the standard error of the mean for
the different brain regions are as follow: cortex: 1629.792±3950.262, peri-ventricular and
hippocampus: -6717.974±3875.621, striatum-caudate putamen-hypothalamus (brain):
2495.001 ±3875.621and the cerebellum: 9054.164±4148.604. The mean ± the standard
error of the mean for the treatment groups was as follow: RYM: -111.950 ± 2556.352,
PYM: 3342.441±3029.712.
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Figure 45: Comparison between young male rats that have not given any drug, and young
male rats that have given 5 mg/kg Prozac for three days (CYM vs. PYM). The x-axis
represents the different brain regions: cortex, peri-ventricular and hippocampus, striatumcaudate putamen-hypothalamus (brain), cerebellum. The y-axis represents the total ng
Evans Blue/mg protein. Two-way ANOVA was performed. Columns represent the mean for
each group and error bars show standard error of mean (SEM). Interaction, P= 0.134,
Region, P=0.245, Treatment, P= 0.982. The n for the animal groups was as follow: CYM
=10 , PYM =7.
Figure 45 shows there was no significant difference in ng Evans Blue/mg protein
for the interaction between the different brain regions and drug treatment groups (P =
0.134). Also, there was no significant difference between the different brain regions for the
young male rats (P = 0.245). In addition, there was no significant difference between the
different drug treatment groups (P =0.982). The outliers were determined by using the
ROUT analysis at medium settings. The CYM had two outliers. The first outlier
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(80868.926) was located at the hippocampus region while the second outlier (40375.985)
was located at the cerebellum region. The root mean square error, which is defined as the
residual mean square. It is used to estimates the common within-group standard deviation
which also known as the standard error of the estimate were as the following. The mean ±
the standard error of the mean: CYM: 3760.815 ± 3939.969, PYM: 1492.191 ± 4097.067.
The mean ± the standard error of the mean for the different brain regions was as follow:
cortex: 969.421 ± 5320.791, hippo: -3701.888 ± 4483.520, brain: 1620.648 ± 7493.500,

Total ng EB/mg Prot

cere: 9516.984 ± 5320.791.

Figure 46: Comparison between young male rats that have given 5 mg/kg of Prozac, and
young male rats that have not given any drug (CYM vs. PYM). The x-axis represents the
different brain regions: cortex, peri-ventricular and hippocampus, striatum-caudate
putamen-hypothalamus, and cerebellum. The y-axis represents the total ng EB/mg protein.
Two-way ANOVA was performed. Columns represent the mean for each group and error
bars show standard error of mean (SEM). Interaction, P= 0.121, Region, P=0.059,
Treatment, P= 0.417. The n of the animal groups of the CYM were as follow: the n for the
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cortex was 10, the n for the hippo was 9, the n for the brain was 10, and the n for the
cerebellum was 9. The n for the PYM=7.

Figure 46 shows the data from Figure 45 without the statistical outliers. The data shows
that there was no significant difference in ng Evans Blue/mg protein for interaction
between the different brain regions and the drug treatment (P = 0.121; Prozac versus
Control). Also, there was no significant difference between the different brain regions in
young male rats (P = 0.059). In addition, there was no significant difference between the
drug treatment (P =0.417). The root mean square error, which is defined as the residual
mean square. It is used to estimates the common within-group standard deviation which
also known as the standard error of the estimate were as the following. The mean ± the
standard error of the mean for the different brain regions are as follow: cortex: 1473.077 ±
3855.508, peri-ventricular and hippocampus:-6560.820 ± 3942.719, striatum-caudate
putamen-hypothalamus (brain): 3173.998 ± 3855.508and the cerebellum: 8913.678 ±
3942.719. The mean ± the standard error of the mean for the treatment groups was as
follow: CYM: 157.526 ± 2541.831, PYM: 3342.441 ± 2957.040.
Summary: When total ng Evans blue in regions is normalized by the amount of
protein measured from the tissue in milligrams. We also compared the different treatment
groups (R-fluoxetine and S-fluoxetine) with Prozac treatment group. We found there was
no significant difference in interaction, region and treatments. The hippocampus showed
the lowest blood brain barrier permeability among the different brain regions and the
cerebellum showed the highest blood brain barrier permeability among the different brain
regions.
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3.6 Comparisons among the Old Males Groups
One Way ANOVA of total ng EB/mg protein
The listed figures represent the comparison of the normalized measurements of
Evans blue among the different old male rat groups (COM vs. SOM, COM vs. ROM and
ROM vs. SOM). The amount of Evans blue was normalized by measuring the total amount
of Evans blue in (ng). Then, dividing it by the amount of the protein concentration in mg
which was determined by a Bradford protein assay.

Figure 47: Comparison between old male rats that have not taken any drug, and old male
rats that have taken 5 mg/kg S-fluoxetine for three days. The x-axis represents the different
brain regions: cortex, peri-ventricular and hippocampus, striatum-caudate putamenhypothalamus (brain), and cerebellum. The y-axis represents the total ng EB/mg protein.
Two-way ANOVA was performed. Columns represent the mean for each group and error
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bars show standard error of mean (SEM). Interaction, P= 0.5154. Region, P= 0.1007.
Treatment, P= 0.5452. The n of the animals groups were as follow: COM = 7, SOM=7.
Figure 47 shows that there was no significant difference in the amount of Evans Blue/mg
protein for interaction between the different brain regions and drug treatment groups (P =
0.5154). Also, there was no significant difference between the different brain regions (P =
0. 1007), although this did show a strong trend. In addition, there was no significant
difference between the drug treatment groups (P =0.5452) comparing control and Sfluoxetine in old male rats. The outliers were determined by using the ROUT analysis at
medium setting. The outliers were found in the SOM group. The outlier 22521.990 was
located in the hippocampus while the outlier 4306.475 was located at the brain region.
The root mean square error, which is defined as the residual mean square. It is used to
estimates the common within-group standard deviation which also known as the standard
error of the estimate were as the following. The mean ± the standard error of the mean
for COM: 18.412 ± 508.142, SOM: -559.024 ± 543.227. The mean ± the standard error
of the mean for the different brain regions was as follow: cortex: 270.698 ± 665.315,
hippo: -2091.274 ± 768.239, brain: 541.472 ± 768.239, cerebellum: 197.881 ± 768.239.
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Figure 48: Comparison between old male rats that have not taken any drug, and old male
rats that have taken 5 mg/kg S-fluoxetine for three days (COM vs. SOM) without outliers.
The x-axis represents the different brain regions: cortex, peri-ventricular and
hippocampus, striatum-caudate putamen-hypothalamus (brain), and cerebellum. The yaxis represents the total ng EB/mg protein. Two-way ANOVA was performed. Columns
represent the mean for each group and error bars show standard error of mean (SEM).
Interaction, P= 0.363. Region, P= 0.001. Treatment, P= 0.509. The n of the SOM for the
different animal groups were as follow: the n for the cortex was 7, the n for the
hippocampus was 6, the n for the brain was 6, and the n for the cerebellum was 7. The n
for the COM = 7.
Figure 48 shows the data from figure 47 without the statistical outliers. The data
shows that there was no significant difference in the amount of Evans Blue/mg protein for
interaction between the different brain regions and the drug treatment groups (P = 0.363).
However, there was a significant difference in the amount of Evans Blue/protein between
the different brain regions (P = 0. 001). There was no significant difference between the
drug treatment groups (P =0.509). The root mean square error, which is defined as the
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residual mean square. It is used to estimates the common within-group standard deviation
which also known as the standard error of the estimate were as the following. The mean ±
the standard error of the mean: COM: -5.023 ± 101.053, SOM: 92.014 ± 105.180. The
mean ± the standard error of the mean for the different brain regions: cortex: 270.698 ±
142.911, the hippo: -498.726 ± 148.747, brain: 250.928 ± 148.747, cerebellum: 151.082 ±
142.911.

Figure 49: Comparison between old male rats that have given R-fluoxetine, and old male
rats that have taken 5 mg/kg S-fluoxetine for three days (ROM vs. SOM). The x-axis
represents the different brain regions: cortex, peri-ventricular and hippocampus, striatumcaudate putamen-hypothalamus (brain), and cerebellum. The y-axis represents the total ng
EB/mg protein. Two-way ANOVA was performed. Columns represent the mean for each
group and error bars show standard error of mean (SEM). Interaction, P= 0.536. Region,
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P= 0.091. Treatment, P= 0.500. The n of the animal groups were as follow: ROM =7, SOM
=7.
Figure 49 shows that there was no significant difference in the amount of Evans
Blue/mg protein for the interaction between the different brain regions and drug treatment
groups (P = 0.536). Also, there was no significant difference between the different brain
regions (P = 0. 091), although the P value shows there is a strong trend. In addition, there
was no significant difference between the drug treatment (P =0.500). The outliers were
determined by using the ROUT analysis at medium setting. The outliers were only found
in the SOM group. The outlier 22521.990 was located in the hippocampus while the outlier
4306.475 was located at the lower brain region. The root mean square error, which is
defined as the residual mean square. It is used to estimates the common within-group
standard deviation which also known as the standard error of the estimate were as the
following. The mean ± the standard error of the mean, ROM: 5.780 ± 137.701, SOM:
120.155 ± 147.132. The mean ± the standard error of the mean for the different brain
regions are as follow: cortex: 260.137 ± 194.739, hippo: -564.159 ± 202.691, brain:
139.670 ± 213.326, cerebellum: 416.222 ± 194.739.
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Figure 50: Comparison between old male rats that have given R-fluoxetine, and old male
rats that have taken 5 mg/kg S-fluoxetine (ROM vs. SOM). The x-axis represents the
different brain regions: cortex, peri-ventricular and hippocampus, striatum-caudate
putamen-hypothalamus (brain), and cerebellum. The y-axis represents the total ng EB/mg
protein. Two-way ANOVA was performed. Columns represent the mean for each group
and error bars show standard error of mean (SEM). Interaction, P= 0.161. Region, P=
0.006. Treatment, P= 0.573. The n for the SOM of the animal groups were as follow: the
n for the cortex was 7, the n for the hippo was 6, the n for the brain was 6, and the n for
the cerebellum was 7. The n for the ROM =7.
Figure 50 shows that there was no significant difference for interaction between the
different brain regions and treatment groups (P = 0.161). Also, there was a significant
difference between the different brain regions (P = 0. 006). In addition, there was no
significant difference between the treatment (P =0.573). The root mean square error, which
is defined as the residual mean square. It is used to estimates the common within-group
standard deviation which also known as the standard error of the estimate were as the
following. The mean ± the standard error of the mean for the different brain regions are as
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follow: cortex: 260.137 ± 194.739, peri-ventricular and hippocampus: -564.159 ± 202.691,
striatum-caudate putamen-hypothalamus (brain): 139.670 ± 213.326 and the cerebellum:
416.222 ± 194.739. The mean ± the standard error of the mean for the treatment groups
was as follow: ROM: 5.780 ± 137.701, SOM: 120.155 ± 147.132.

Figure 51: Comparison between old male rats that have given 5 mg/kg R-fluoxetine, and
old male rats that have not taken any drug (ROM vs. COM). The x-axis represents the
different brain regions: cortex, peri-ventricular and hippocampus, striatum-caudate
putamen-hypothalamus (brain), and cerebellum. The y-axis represents the total ng EB/ mg
Protein. Two-way ANOVA was performed. Columns represent the mean for each group
and error bars show standard error of mean (SEM). Interaction, P= 0.5022. Region, P =
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0.0003. Treatment, P= 0.9587. The n of the animal groups were as follow: COM =7, ROM
=7.
Figure 51 shows that there was no significant difference for ng Evans Blue/mg
protein in interaction between the different brain regions and drug treatment groups (P =
0.5022). However, there was a significant difference between the different brain regions
(P = 0. 0003), with the hippocampal region showing significantly lower permeability. In
addition, there was no significant difference between the drug treatments for the old male
rats (P =0.9587). The root mean square error, which is defined as the residual mean square.
It is used to estimates the common within-group standard deviation which also known as
the standard error of the estimate were as the following. The mean ± the standard error of
the mean for the different treatment groups were as follow: COM: -5.023 ± 146.680, ROM:
71.334 ± 146.680. The mean ± the standard error of the mean for the different regions were
as follow: cortex: 336.672 ±207.437, hippocampus: -705.451±207.437, brain:
95.381±207.437, cerebellum: 406.022±207.437.
Summary: Our statistical analysis for different drug treatments in old male rats
showed that there was a significant difference for the blood brain barrier permeability for
the different brain regions with the hippocampus showing the lowest blood brain barrier
permeability. S-fluoxetine and R-fluoxetine seemed to have no effect on the blood brain
barrier permeability because the treatment effect was not significantly different. Also, there
was no interaction between the different brain regions and the treatment groups.
3.7 Comparison among Old Female Rats

Two-Way ANOVA of total ng EB/mg Protein
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In the next set of figures, we normalized the amount of Evans blue in a region by
dividing the total ng Evans blue in that region by the protein concentration in mg,
determined by a Bradford protein assay. Then, we compared the total amount of ng Evans
blue divided by the amount of protein (mg) in old female rats versus old male rats.

Figure 52: Comparison between old female rats that have given 5 mg/kg R-fluoxetine, and
old female rats that have given 5 mg/kg S-fluoxetine (ROF vs. SOF) for three days. The xaxis represents the different brain regions: cortex, peri-ventricular and hippocampus,
striatum-caudate putamen-hypothalamus (brain), cerebellum. The y-axis represents the
total ng EB/mg protein. Two-way ANOVA was performed. Columns represent the mean for
each group and error bars show standard error of mean (SEM). Interaction, P=0.1827.
Region, P=0.0009. Treatment, P=0.4934. The n of the animal groups were as follow: SOF
=6, ROF=7.
Figure 52 shows that there was no significant difference in the ng Evans Blue/mg
protein for the interaction between the different brain regions and drug treatment groups
(P = 0.1827). However, there was significant difference between the different brain regions
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for the old female rats (P = 0.0009), with the hippocampal region showing the lowest
permeability to Evan Blue. In addition, there was no significant difference between the
drug treatment groups (P =0.4934: R-fluoxetine versus S-Fluoxetine). Statistical outliers
were determined by using the ROUT analysis at medium setting. The outlier (9420.832)
was found in the cortical region of the old female rats receiving R-fluoxetine. The root
mean square error, which is defined as the residual mean square. It is used to estimates the
common within-group standard deviation which also known as the standard error of the
estimate were as the following. The mean ± the standard error of the mean for SOF: 212.614 ± 582.205, ROF: -797.972 ± 504.204. The mean ± the standard error of the mean
for the brain regions are as follow: cortex: -173.417 ± 793.412, hippo: -3495.600 ±
793.412, brain: -88.753 ± 793.412, cerebellum: 1736.597 ± 695.868.

Figure 53: Comparison between old female rats that have taken 5mg/kg R-fluoxetine
(ROF), and old female rats that have taken 5 mg/kg S-fluoxetine (SOF) for three days. The
x-axis represents the different brain regions: cortex, peri-ventricular and hippocampus,
striatum-caudate putamen-hypothalamus, and cerebellum. The y-axis represents the total
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ng EB. Two-way ANOVA was performed. Columns represent the mean for each group and
error bars show standard error of mean (SEM). Interaction, P=0.106. Region, P<0.001.
Treatment, P=0.451. The n for the SOF = 6, the n for the ROF was as follow: the n for the
cortex = 6, the n for the hippocampus = 7, the n for the lower brain region = 7, the n for
the cerebellum = 7.
Figure 53 shows the same data as Figure 52 but without the statistical outliers. The data
shows that there was no significant difference for ng Evans Blue/mg protein for interaction
between the different brain regions and drug treatment groups (P = 0.106; S-fluoxetine
versus R-fluoxetine). However, there was a significant difference between the different
brain regions between old female rats given different Fluoxetine enantiomers as drug
treatments (P < 0. 001), with the hippocampal region showing the lowest permeability to
Evan Blue. In addition, there was no significant difference between the drug treatment (P
=0.451; Fluoxetine enantiomers). The root mean square error, which is defined as the
residual mean square. It is used to estimates the common within-group standard deviation
which also known as the standard error of the estimate were as the following. The mean ±
the standard error of the mean for the different brain regions are as follow: cortex: -173.417
± 793.412, peri-ventricular and hippocampus: -3495.600 ± 793.412, striatum-caudate
putamen-hypothalamus (brain): -88.753 ± 793.412 and the cerebellum: 1736 ± 695.868.
The mean ± the standard error of the mean for the treatment groups was as follow: SOF: 212.614 ± 582.205, ROF: -797.972 ± 504.204.
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Figure 54: Comparison between old female rats that have given 5 mg/kg R-fluoxetine for
three days, and old female rats that have not given any drug (ROF vs. COF). The x-axis
represents the different brain regions: cortex, peri-ventricular and hippocampus, striatumcaudate putamen-hypothalamus (brain), cerebellum. The y-axis represents the total ng
EB/mg protein. Two-way ANOVA was performed. Columns represent the mean for each
group and error bars show standard error of mean (SEM). Interaction, P=0.9402. Region,
P=0.0061. Treatment, P=0.3101. The n of the animal groups were as follow: COF = 7,
ROF = 7.
Figure 54 shows that there was no significant difference in the total ng Evans Blue/mg
protein for interaction between the different brain regions and drug treatment groups (P =
0.9402; control versus R-fluoxetine). However, there was a significant difference between
the different brain regions for the old female rats (P = 0.0061), with the hippocampal region
showing the lowest permeability to Evans Blue. There was no significant difference
between the drug treatment groups (P =0.3101; control versus R-fluoxetine). The ROUT
analysis at medium setting was used to determine the outliers. One outlier was found at the
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cortex in the ROF group. The outlier was 9420.832. The COF group had two outliers. One
outlier was found in the cortex which was 4503.975. The other outlier was found in the
hippocampus, the outlier was -12021.576. Cere: 706.182. The root mean square error,
which is defined as the residual mean square. It is used to estimates the common withingroup standard deviation which also known as the standard error of the estimate were as
the following. The mean ± the standard error of the mean: COF: 245.048 ± 346.805, ROF:
-797.972 ± 333.199. The mean ± the standard error of the mean for the different brain
regions was as follow: the cortex: -367.930 ± 490.456, hippo: -1568.491 ± 490.456, brain:
124.390 ± 471.215, cerebellum: 706.182 ± 471.215.

Figure 55: Comparison between old female rats that have given 5 mg/kg R-fluoxetine for
three days, and old female rats that have not given any drug (ROF vs. COF). The x-axis
represents the different brain regions: cortex, peri-ventricular and hippocampus, striatumcaudate putamen-hypothalamus (brain), and cerebellum. The y-axis represents the total ng
EB. Two-way ANOVA was performed. Columns represent the mean for each group and
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error bars show standard error of mean (SEM). Interaction, P=0.917. Region, P=0.013.
Treatment, P=0.035. The number of animals, n for the COF different brain regions were
as follow: the n for the cortex = 6, the n for the hippocampus = 6, the n for the lower brain
region = 7, the n for the cerebellum = 7.
Figure 55 the same data as Figure 54, but without the statistical outliers. The data shows
that there was no significant difference in ng Evans Blue/mg protein for interaction
between the different brain regions and drug treatment groups (P = 0.917). However, there
was a significant difference between the different brain regions for the old female groups
being compared (P = 0.013), with cerebellum showing increased permeability and the
hippocampus showing the lowest permeability. There was also a significant difference
between the drug treatment groups (P =0.035), with the R-fluoxetine tightening the blood
brain barrier compared to the control animals. The root mean square error, which is defined
as the residual mean square. It is used to estimates the common within-group standard
deviation which also known as the standard error of the estimate were as the following.
The mean ± the standard error of the mean for the different brain regions are as follow:
cortex: -368.180 ± 490.460, peri-ventricular and hippocampus: -1568.492 ± 490.460,
striatum-caudate putamen-hypothalamus (brain): 124.390 ± 471.219and the cerebellum:
706.182 ±471.219. The mean ± the standard error of the mean for the treatment groups was
as follow: COF: 244.922 ± 346.808, ROF: -797.972 ± 333.202.
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Total ng EB/mg Prot

Figure 56: Comparison between old female rats that have given 5 mg/kg S-fluoxetine for
three days, and old female rats that have not given any drug (SOF vs. COF). The x-axis
represents the different brain regions: cortex, peri-ventricular and hippocampus, striatumcaudate putamen-hypothalamus (brain), cerebellum. The y-axis represents the total ng
EB/mg protein. Two-way ANOVA was performed. Columns represent the mean for each
group and error bars show standard error of mean (SEM). Interaction, P=0.015. Region,
P<0.001. Treatment, P=0.465. The n of the animal groups were as follow: COF = 7, SOF
= 6.
Figure 56 that there was a significant difference in ng Evans Blue/mg protein for the
interaction between the different brain regions and the drug treatment groups (P = 0.015;
control versus S-fluoxetine). Also, there was significant difference between the different
brain regions in these old female drug groups (P < 0.001), with the hippocampus showing
the lowest permeability of the BBB and the cerebellum showing the highest permeability.
There was no significant difference between the different drug treatment groups (P
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=0.465). The ROUT analysis was used to determine the outliers. The outlier 4503.975 was
located in the cortex while the outlier -12021.576 was found in the hippocampus. The root
mean square error, which is defined as the residual mean square. It is used to estimates the
common within-group standard deviation which also known as the standard error of the
estimate were as the following. The mean ± the standard error of the mean: COF: 245.048
± 433.250, SOF: -212.614 ± 447.155. The mean ± the standard error of the mean for the
different brain regions are as follow: Cortex: 315.195 ± 585.463, the hippo: -2695.107 ±
676.034, the brain: 242.768 ± 651.443, the cerebellum: 2202.011 ± 571.353.

Figure 57: Comparison between old female rats that have given no drugs, and old female
rats that have taken 5 mg/kg S-fluoxetine for three days (COF vs. SOF). The x-axis
represents the different brain regions: cortex, peri-ventricular and hippocampus, striatumcaudate putamen-hypothalamus, and cerebellum. The y-axis represents the total ng EB.
Two-way ANOVA was performed. Columns represent the mean for each group and error
bars show standard error of mean (SEM). Interaction, P=0.056. Region, P<0.001.
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Treatment, P=0.544. The animal numbers, n for the SOF = 6, the n for the ROF different
brain regions were as follow: the n for the cortex = 6, the n for the hippocampus = 7, the
n for the lower brain region = 7, and the n for the cerebellum = 7.
Figure 57 shows the same data as Figure 56, but with the statistical outliers removed. The
data shows that we just missed having a significant difference in ng Evans Blue/mg protein
for interaction between the different brain regions and drug treatment groups (P = 0.056;
control versus S-fluoxetine), showing a very strong trend. Interestingly, the S-fluoxetine
increased permeability in the cerebellum, but appears to lower permeability in the
hippocampus. Also, there was a significant difference between the different brain regions
between the groups (P < 0. 001), with the hippocampal region showing low BBB
permeability and the cerebellum showing high BBB permeability. In addition, there was
no significant difference between the drug treatment groups (P =0.544; control versus SFluoxetine). The root mean square error, which is defined as the residual mean square. It
is used to estimates the common within-group standard deviation which also known as the
standard error of the estimate were as the following. The mean ± the standard error of the
mean for the different brain regions are as follow: cortex: 315.195 ± 762.731, periventricular and hippocampus: -2695.107 ± 762.731, striatum-caudate putamenhypothalamus (brain): 242.768 ± 734.986and the cerebellum: 2202.011 ± 734.986. The
mean ± the standard error of the mean for the treatment groups was as follow: COF:
245.048 ± 519.714, SOF: -212.614 ± 539.332.

Summary: When total ng Evans blue in regions is normalized by the amount of
protein measured from the tissue in milligrams for old female rats, we compared the blood
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brain barrier permeability under different drug treatments. The analysis showed that there
was a significant difference in the total ng Evans Blue/mg protein among the different brain
regions in old female rats with the hippocampus showing the lowest blood brain barrier
permeability and the cerebellum showing the highest permeability. When we compared
R-fluoxetine to control in old female rats, we did see a significant drug treatment effect on
the permeability, with the R-fluoxetine consistently reducing the permeability
3.8 Comparison of All treatment groups across a Brain Regions
3.8.1 Cortex
Two-Way ANOVA of total ng EB/mg Protein
In the coming figures, we compared the total amount of Evans blue in the cortex
region for the young male rats, old male rats and old female rats. We normalized the amount
of Evans blue in a region by dividing the total ng Evans blue in that region by the protein
concentration in mg, determined by a Bradford protein assay.
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Figure 58: Comparison between cortex region for the young male, old male and old female
rats. The x-axis represents the different treatment groups. The y-axis represents the total
ng Evans Blue/mg protein. Columns represent the mean for each group and error bars
show standard error of mean (SEM). Two-way ANOVA was performed. Interaction,
P=0.592. Treatment, P=0.609. Age and gender P=0.622. The n of the animal groups were
as follow: CYM =10, ROM =7, SOF=6.
Figure 58 shows that there no significant difference in the amount of Evans Blue/mg
protein in the cortex for the interaction between the different drug treatments and the
different animal groups (age and gender differences) (P = 0.592). Also, there is no
significant difference between the different drug treatments for this region of the brain (P
= 0.609). In addition, there is no significant difference between the animal groups (young
male rats, old male rats, old female rats) (P= 0.622). The outliers were determined by using
the ROUT analysis at medium setting. The outliers were found at the RYM, COF, and ROF
groups. The outlier at the cortex region of the RYM was 134723.4088. The outlier at the
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cortex region of the COF was -4503.975. The outlier at the cortex region of the ROF was
-9420.832. The root mean square error, which is defined as the residual mean square. It is
used to estimates the common within-group standard deviation which also known as the
standard error of the estimate were as the following. The mean ± the standard error of the
mean for the cortex of the young males: 3673.030 ± 2812.087, cortex of the old males:
289.169 ± 3515.386, the cortex of the old female: -295.748 ± 3611.716. The mean ± the
standard error of the mean for the treatment groups was as follow: the control: -234.732 ±
3334.988. R-fluoxetine treatment group: 3925.951 ± 3295.452. S-fluoxetine treatment
group: -24.768 ± 3365.726.

Figure 59: Comparison between Cortex regions for the young males, old males and old
female rats that have not taken any drug, have taken 5 mg/kg R-fluoxetine and the ones
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that have taken the 5 mg/kg S-fluoxetine. The x-axis represents the different drug treatment
groups. The y-axis represents the total ng Evans Blue/mg protein. Columns represent the
mean for each group and error bars show standard error of mean (SEM). Two-way
ANOVA was performed. Interaction, P=0.970. Treatment, P=0.841. Age and gender
P=0.423. The n of the animal groups were as follow: the n for the cortex of the CYM = 10,
the n for the hippocampus =9, the n for the lower brain region = 10, the n for the
cerebellum =9, ROM =7, SOF =6.
Figure 59 shows the data from Figure 58 without the statistical outliers. The data
shows that there was no significant difference in the ng Evans Blue/mg protein for the
interaction between the different drug treatments and the age/gender of the animals (P =
0.970). Also, there was no significant difference between the different drug treatments for
the cortex (P = 0.841). In addition, there was no significant differences in the BBB
permeability between young males, old males and old females (P = 0.423) in the cortex.
The root mean square error, which is defined as the residual mean square. It is used to
estimates the common within-group standard deviation which also known as the standard
error of the estimate were as the following. The mean ± the standard error of the mean for
the cortex of the young male: -379.011 ± 399.901, hippocampus of the old males: 333.287
± 484.877, the hippocampus of the old females: 444.361 ± 517.246. The mean ± the
standard error of the mean: R-group: 357.508 ± 426.051, S-group: -81.992 ± 413.714,
control group: -9.232 ± 594.026.
3.8.2 Hippocampus
Two-Way ANOVA of total ng EB/mg Protein: All treatment groups compared across the
hippocampal brain region
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In the following set of figures, we measured the amount of the protein concentration
in mg by using the Bradford protein assay. Then, we normalized the data by dividing the
total ng Evans blue in that region by the amount of the protein (mg). Then, we compared
the total amount of Evans blue (ng) divided by the amount of protein (mg) in the
hippocampus region for the young male, old male and old female rats with the following
drug treatment: 1) control, 2) 5 mg/kg R-fluoxetine and 3) 5 mg/kg S-Fluoxetine.

Figure 60: Comparison between hippocampal region for the young males, old males and
old female rats that have not taken any drug, have taken 5 mg/kg R-fluoxetine and the ones
that have taken the 5 mg/kg S-fluoxetine. The x-axis represents the different drug treatment
groups. The y-axis represents the total ng Evans Blue/mg protein. Columns represent the
mean for each group and error bars show standard error of mean (SEM). Two-way
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ANOVA was performed. Interaction, P=0.822. Drug Treatment, P=0.506. Age and gender
P=0.445. The n of the animal groups were as follow: CYM =10, ROM =7, SOF=6.
Figure 60 shows a comparison of the different drug treatments for all of the different age
and gender groups on blood brain barrier permeability in the hippocampal region. There
was no significant difference in the ng Evans Blue/mg protein for interaction between the
different drug treatments (listed on the X axis) and the age or gender of the animals (P =
0.822). Also, there was no significant difference between the different drug treatments (P
= 0.506) for this region. In addition, there was no significant difference in the blood brain
barrier permeability in this region based on either age or gender (P = 0.445). The outliers
were determined by the ROUT analysis at medium setting. The outliers were found in the
CYM, SOM and COF groups. The outlier at the hippocampus region in the CYM was
80868.926. The outlier at the hippocampus of the SOM was -22521.990. The outlier at the
COF was -12021.576. The root mean square error, which is defined as the residual mean
square. It is used to estimates the common within-group standard deviation which also
known as the standard error of the estimate were as the following. The mean ± the standard
error of the mean for the hippo region of the young male: 1166.939 ± 2262.869, the hippo
region of the old male: -1694.846 ± 2564.188, for the hippo region of the old females: 3122.296 ± 2634.453. The mean ± the standard error of the mean for the treatment groups
was as follow: control: 1079.616 ± 2432.602, R-fluoxetine treatment group: -1767.342 ±
2403.764, S-fluoxetine: -2962.479 ± 2634.453.
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Figure 61: Comparison in BBB permeability (ng Evans Blue/mg protein) in the
hippocampal region for the different groups (young males, old males and old female rats)
and the different drug treatments (control: that have not taken any drug, have taken 5
mg/kg R-fluoxetine and the ones that have taken the 5 mg/kg S-fluoxetine). The x-axis
represents the different drug treatment groups. The y-axis represents the total ng Evans
Blue/mg protein. Columns represent the mean for each group and error bars show
standard error of mean (SEM). Two-way ANOVA was performed. Interaction, P=0.781.
Drug Treatment, P=0.884. Age and gender P=0.518. The n of the animal groups were as
follow: the n for the cortex = 10, the n for the hippocampus = 9, the n for the lower brain
region =10, the n for the cerebellum =9, ROM =7, SOF= 6.
Figure 61 shows the data from Figure 60 but with the statistical outliers removed.
The data indicates that there was no significant difference for ng Evans Blue/mg protein in
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the interaction between the different drug treatments and the age & gender of the animals
(P = 0.781). Also, there was no significant difference between the different drug treatments
in this brain region (P = 0.884). In addition, there was no significant difference between
the young males, old males and the old females (P = 0.518). The root mean square error,
which is defined as the residual mean square. It is used to estimates the common withingroup standard deviation which also known as the standard error of the estimate were as
the following. The mean ± the standard error of the mean for the hippocampus of the young
male: -1381.897 ± 1315.295, the hippocampus of the old male: -468.675 ± 1454.796, the
hippocampus of the old females: -1803.768 ± 1921.934.
3.8.3 Brain
Two-Way ANOVA of total ng EB/mg Protein
In the following figures, we divided the total amount of Evans blue in a region (ng)
by the protein concentration (mg) which was determined by using Bradford protein assay
in order to normalize the data. Then, we compared the total amount of Evans blue (ng)
divided the amount of the protein (mg) in the lower brain region (striatum, caudate
putamen, hypothalamus) for the young male, old male and old female receiving the
following drug treatments: 1) control, 2) 5 mg/kg R-fluoxetine, and 3) 5 mg/kg Sfluoxetine.
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Figure 62: Comparison of Blood Brain for the young males, old males and old female rats.
The x-axis represents the different drug treatment groups. The y-axis represents the total
ng Evans Blue/mg protein. Columns represent the mean for each group and error bars
show standard error of mean (SEM). Two-way ANOVA was performed. Interaction,
P=0.371. Drug Treatment, P=0.040. Age and gender P<0.0001. The n of the animal
groups were as follow: CYM =10, ROM =7, SOF = 6.
Figure 62 shows that there no significant difference in the ng Evans Blue/mg protein for
interaction between the different drug treatments and the different animal groups (age and
gender differences) (P = 0.371). Also, there is no significant difference between the
different drug treatments in the lower brain (P = 0.040), although the low P value does
indicate a strong trend here. There is significant difference between in the blood brain
barrier permeability of the young male rats and the older male and female rats, P < 0.0001.
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The younger rats show enhanced permeability in this region, which includes the choroid
plexus, while the older animals show reduced permeability. The statistical outliers were
determined by ROUT analysis at medium setting. The outlier (4306.475) at brain region
was found at the SOM group. The root mean square error, which is defined as the residual
mean square. It is used to estimates the common within-group standard deviation which
also known as the standard error of the estimate were as the following. The mean ± the
standard error of the mean for the brain region of the young male: 3047.635 ± 457.498,
brain of the old males: 757.866 ± 518.418, brain of the old females: 92.802 ± 532.624. The
mean ± the standard error of the mean for the treatment groups was as follow: control:
1157.955 ± 491.814, R-fluoxetine treatment group: 434.820 ± 485.984, S-fluoxetine
treatment group: 2305.529 ± 532.624.
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Figure 63: Comparison between brain regions for the young males, old males and old
female rats that have not taken any drug, have taken 5 mg/kg R-fluoxetine and the ones
that have taken the 5 mg/kg S-fluoxetine. The x-axis represents the different treatment
groups. The y-axis represents the total ng Evans Blue/mg protein. Columns represent the
mean for each group and error bars show standard error of mean (SEM). Two-way
ANOVA was performed. Interaction, P=0.464. Treatment, P=0.645. Age and gender
P<0.0001. The animal number, n for the different groups of the CYM were as follow: the
n for the cortex = 10, the n for the hippocampus =9, the n for the lower brain region =10,
and the n for the cerebellum =9, ROM=7, SOF=6.
Figure 63 shows the same data for Figure 62, but with the one statistical outlier
removed. This data indicates that there was no significant difference in the ng Evans
Blue/mg protein for the interaction between the drug treatment and the age/gender of the
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animal groups (P = 0.464). Also, there was no significant difference between the different
drug treatments (P = 0.645). However, there was a significant difference young males, old
males and old females (P <0.0001), with the young males showing enhanced permeability
in the lower brain region. The root mean square error, which is defined as the residual mean
square. It is used to estimates the common within-group standard deviation which also
known as the standard error of the estimate were as the following. The mean ± the standard
error of the mean: the brain of the young male: 2983.164 ± 532.173, the brain of the old
male: 611.074 ± 589.604, the brain of the old female: 35.867 ± 638.137. The mean for the
different treatment groups was as follow: control: 1135.939 ± 513.319, R-group: 252.743
± 504.818, S-group: 2613.634 ± 629.453.
3.8.4 Cerebellum
Two-Way ANOVA of total ng EB/mg Protein
The figures below represent the normalized amount of Evans blue in the cerebellum
region of the brain in young male, old male and old female with different drug treatment:
1) control; 2) 5 mg/kg R-fluoxetine, 3) 5 mg/kg S-fluoxetine. The data were normalized by
dividing the amount of Evans blue (ng) by the amount of protein (mg) that was measured
by using the Bradford protein assay.
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Figure 64: Comparison between cerebellum region for the young males, old males and old
female rats that have not taken any drug (control), have taken 5 mg/kg R-fluoxetine and
the ones that have taken 5 mg/kg S-fluoxetine. The x-axis represents the different drug
treatment groups. The y-axis represents the total ng Evans Blue/mg protein. Columns
represent the mean for each group and error bars show standard error of mean (SEM).
Two-way ANOVA was performed. Interaction, P=0.287. Treatment, P=0.738. Age and
gender P=0.560. The n of the animal groups were as follow: CYM =10, ROM = 7, SOF
=6.
Figure 64 shows that there was no significant difference in the ng Evans Blue/mg
protein for interaction between the different animal groups (age and gender differences)
and the drug treatments (P = 0.287) in the cerebellum. Also, there is no significant
difference between the different the different drug treatments for this region of the brain (P
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= 0.738). In addition, there is no significant difference between the animal groups (age and
gender differences) in the cerebellum (P = 0.560). The statistical outliers were determined
by using the ROUT analysis at medium setting. The outliers were found in the CYM, RYM,
and SYM groups. The CYM’s outlier was 40375.9851. The SYM’s outlier was
15175.1144. The RYM’s outliers were 24064.006, 41496.548, and 197113.231. The root
mean square error, which is defined as the residual mean square. It is used to estimates the
common within-group standard deviation which also known as the standard error of the
estimate were as the following. The mean ± the standard error of the mean for the
cerebellum of the young male: 11987.928 ± 6323.456, the cerebellum of the old male:
9720.010 ± 6541.153, the cerebellum of the old female: 1613.656 ± 7553.072.

Figure 65: Comparison between cerebellum region for the young males, old males and old
female rats that have not taken any drug (control), have taken 5 mg/kg R-fluoxetine and
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the ones that have taken the 5 mg/kg S-fluoxetine. The x-axis represents the different
treatment groups. The y-axis represents the total ng Evans Blue/mg protein. Columns
represent the mean for each group and error bars show standard error of mean (SEM).
Two-way ANOVA was performed. Interaction, P=0.103. Drug Treatment, P=0.387. Age
and gender P=0.017. The animal numbers, n for the CYM different brain regions were as
follow: the n for the cortex =10, the n for the hippocampus =9, the n for the lower brain
region=10, the n for the cerebellum =9, ROM = 7, SOF=6.
Figure 65 shows the data from Figure 64, but with the statistical outliers removed.
The data indicates that there was no significant difference in ng Evans Blue/mg protein for
the interaction between the drug treatment and the different ages/gender of the animals
groups (P = 0.103), but the low P value indicates a strong trend. Also, there was no
significant difference between the different drug treatments (P = 0.387) in this region of
the brain. There was a significant difference young males, old males and old females (P =
0.017), showing an influence of age and gender on the permeability.

In particular, the

female rat had greater permeability in the cerebellum in the control condition and in the
presence of S-fluoxetine. The root mean square error, which is defined as the residual mean
square. It is used to estimates the common within-group standard deviation which also
known as the standard error of the estimate were as the following. The mean ± the standard
error of the mean for the cerebellum of the young males: -84.739 ± 391.646, cerebellum of
the old males: 327.434 ± 417.002, the cerebellum of the old females: 1490.404 ± 457.757.
The mean ± the standard error of the mean for the different treatment groups: control:
586.748 ± 496.978, R-treatment group: 426.862 ± 378.740, S-treatment group: 906.113 ±
361.394.
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Summary:
Two-Way ANOVA of Total ng EB/mg Protein
Total ng Evans blue in regions was normalized by the amount of protein measured
from the tissue in milligrams. In this analysis we compared the different brain region
(cortex, hippocampus, brain region and the cerebellum) among the young male rats, the
old male rats and old female rats for each of the different drug treatments. In the cortex,
our analysis showed that there were no significant difference in the interaction between the
drug treatment and the age and gender factor of the animal groups. Also, there no
significant difference in the either the drug treatments nor the age and gender factor.
In hippocampus, our analysis showed that there was no significant difference in the
interaction between the drug treatment and the age and gender factor. Also, there were no
significant difference in the drug treatment, or the age and gender factor in this region of
the brain.
In the lower brain, our analysis showed that there was a significant difference in age and
gender. The young males showed the highest blood brain barrier permeability, while older
animals had much lower permeability. In the young male rats, we saw a strong trend
(P=0.1319) for differences in drug treatment, with the S-fluoxetine increasing the blood
brain barrier permeability while the R-fluoxetine decreased the blood brain barrier
permeability.

There was no significant difference in the interactions between drug

treatment and age/gender in this region.
In cerebellum, there were no significant difference in the interaction between drug
treatment and age /gender of the animal groups, but the P-value indicated a very strong
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trend. S-fluoxetine increased the blood brain barrier permeability while the R-fluoxetine
decreased the blood brain barrier permeability in old female rats. There was a significant
difference in the BBB permeability when age and gender was considered, with an increase
in the blood brain barrier in the old female rats compared to the two male groups.
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IV. Discussion
The following table represents significant differences in BBB permeability
(measured with Evans Blue permeability based on either Age or the interaction between Age
and the region of the brain. In Figure 63, we see a highly significant P value (<0.0001) based
on age, when we examined permeability in the lower brain region across the three basic
groups (young males (YM), old males (OM) and old females (OF). The YM had enhanced
permeability in the lower brain region compared to either the OM or OF (Holm-Sidak posthoc analysis). The lower two rows in this table refer to the analysis on Figure 34, which
compares COM and CYM. We see an significant interaction (P = 0.0302) between age and
region. In the middle row, we see an increased permeability of the lower Brain region
compared to the Cortex, Hippocampus and Cerebellum within the CYM. In the last row, we
see another interaction between age in region, with CYM showing enhanced permeability
compared to COM, but only in the Brain region (Holm-Sidak post-hoc analysis).
P-Value

The Animal
Groups

<0.0001 Brain
0.0302 COM vs. CYM

Variable
Age

Significant difference
Increased permeability in YM
compared to either OM or OF

Region
and Age Brain
Interaction

0.0302 COM vs. CYM

Figure 63
Figure 34

Increased permeability in
Brain versus Cortex,
Hippo and Cere within
CYM
Brain

Age and CYM
Figure 34
Region
versus
Interaction COM
Table 4: Significant P-values for the Age. YM: young males; OM old males; OF old
females; COM: control old males; CYM control young males; Brain: lower brain
region; Hippo: hippocampus; Cere: Cerebellum.
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The lower brain region showed more blood brain barrier permeability in the young males
compared to the old males. It contains a region called the choroid plexuses. The choroid
plexuses have important functions which involve the production of cerebrospinal fluid and
regulating the movement of molecules across the brain (116). That regulation plays an
important role in ensuring having a homeostatic state in the brain. However, as we get older
the brain function changes due to changes in its structure. These changes cause changes in
cerebrospinal fluid homeostasis. For example, the hippocampus, the prefrontal cortex and
the choroid plexus decreases in size with aging. The size of the choroid plexuses is changed
by changing the height of its epithelial cells and the total volume and length of its apical
microvilli (117). The change in the choroid plexuses size cause a decrease in the
cerebrospinal fluid production due to a decrease in the expression of certain proteins in the
choroid plexuses (118). The following proteins are the main proteins that are associated with
chorodial CSF production: carbonic anhydrase II, aquaporin 1 (AQP1) and sodiumpotassium exchanging ATPase (Na, K-ATPase) (118). In addition, the blood vessel’s wall
gets thicker with aging (117), so that electrolytes that could cross in young rats can no longer
cross well in older rats.
4.2 The results of the total ng EB/mg protein in male versus female (Gender difference)
The next table represents significant differences in BBB permeability based on gender
differences. We compared the blood brain barrier’s permeability under different drug
treatments by measuring the total amount of Evans blue in different brain regions. In figure
65, we saw a significant increase in the BBB permeability in the cerebellum (P value
of0.0149) based on gender. The results showed that old females showed the highest
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permeability for the blood brain barrier in the cerebellum when compared to old males and
young males (Holm-Sidak post-hoc analysis). The cerebellum is the region of the brain that
is the focus for classical conditioning with the eyeblink response and coordination of motor
control. Other studies have shown that the cerebellum has increased blood brain barrier
permeability when the body is trying to clear viruses, but ours is the first report of a gender
difference of BBB permeability. One other study has shown that removing the ovaries
from female rats, which would cause premature estrogen loss, caused a significant increase
in BBB permeability, but they did not evaluate regional changes in permeability.

Our

female rats at 10 months of age are generally thought to have lost their estrogen due to
menopause. We would really like to test the BBB permeability of the cerebellum in young
female rats, to determine if the increase in permeability in the cerebellum in old female rats
is related to estrogen loss. Research studies found that there is a sex differences in response
to selective serotonin reuptake inhibitor. Studies have found that females respond better
than males in response to selective serotonin reuptake inhibitor (119).

P-Value

The Animal
Groups

Variable

Significant difference

Increased
permeability
in Figure 65
cerebellum old females versus
either old males or young males
Table 5: Significant P-values for the gender.
0.0149 Cerebellum

Gender

4.3 Comparison of All treatment groups across a Brain region
Lower Brain Region
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We measured the permeability for the blood brain barrier for the lower brain region
by using Evans blue method. Then, we normalized the data by measuring the amount of
Evans blue divided the concentrations of the protein. Table 9 represents the significant pvalues in the lower brain region of the brain.
The Animal
Groups
0.0012 CYM
0.0164 SYM

P-Value

Significant difference

Variable

Increased permeability

Related
Figure
Figure 14
Figure 18
Figure 34

Increased permeability in
< 0.001 COM vs. CYM
brain vs. hippo, cortex and
cerebellum within CYM
Increased permeability in Figure 36
Brain vs. hippo, brain vs.
Region
cortex,
and
brain
vs.
Brain
cerebellum. The increased
permeability of brain vs.
< 0.0001 CYM vs. SYM
hippo is within CYM. The
increased permeability of
brain vs. hippo, brain vs.
cortex
and
brain
vs.
cerebellum is within SYM
Region
Increased permeability in
Figure 34
and Age
brain vs. hippo, brain vs.
< 0.001 COM vs. CYM
In
cortex, and brain vs.
cerebellum within CYM
Table 6: Significant P-values in the lower brain region of the brain. COM: control old
males; CYM control young males; SYM: S-fluoxetine young males; Brain: lower brain
region; Hippo: hippocampus

In figure 14, we found a significant P value in the brain region of CYM (0.0012),
the lower brain region showed the highest blood brain barrier permeability. In figure 18,
we saw a significant P value in the brain region of SYM (0.0164), and the lower brain
region showed the highest blood brain barrier permeability among the different brain
regions. In the comparison between COM vs. CYM, we saw a significant P value (<0.001)
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associated with the lower brain region. There was an increased permeability in brain vs.
hippo, cortex and cerebellum within CYM (Holm-Sidak post-hoc analysis). In figure 36,
we found out that the significant P value is < 0.0001: We saw an increased permeability in
brain vs. hippo, brain vs. cortex, and brain vs. cerebellum. The increased permeability of
brain vs. hippo is within CYM. The increased permeability of brain vs. hippo, brain vs.
cortex and brain vs. cerebellum is within SYM. The last row of the table, in figure 34, we
saw a significant p value (<0.001) with an increased permeability in brain vs. hippo, brain
vs. cortex and brain vs. cerebellum within CYM.
Hippocampus
Evans blue method was used to measure the permeability of the blood brain barrier.
Then, the results were normalized by dividing the amount of Evans blue by the amount of
the protein concentrations that was measured by using Bradford protein assay. We found
that the hippocampus showed the lowest permeability of all of the tested brain regions for
the following groups: control old males, old males that have given 5 mg/kg of R-fluoxetine,
old females that given 5 mg/kg of S-fluoxetine and old females group that have given 5
mg/kg of R-fluoxetine (see Table 7) .
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P-value
0.0074
0.0221
0.0136
0.0028

Animal
Group(s)
COM
ROM
SOF
ROF

Significant
Difference

Variable

Decreased
permeability

Related
Figure
Figure 20
Figure 23
Figure 26
Figure 28
Figure 48

Decreased
permeability in
hippocampus
0.001 COM vs. SOM
compared to cortex,
or lower brain, or
cerebellum within
COM
Decreased
Figure 50
permeability in
0.006 ROM vs. SOM
hippocampus versus
cerebellum or lower
Region
Hippocampus brain region
Decreased
Figure 51
permeability in
0.001 COM vs. ROM
hippocampus
versus cerebellum
within ROM
Decreased
Figure 55
permeability in
0.013 COF vs. ROF
hippocampus versus
cerebellum within
ROF
Decreased
Figure 57
permeability in
hippocampus versus
<0.001 COF vs. SOF
cerebellum, cortex
or lower brain
regions
Table 7: Significant P-values for the hippocampus region of the brain. COM: control old
males, ROM: R-fluoxetine treated old males, SOF: S-fluoxetine old females, ROF: Rfluoxetine old females, SOM: S-fluoxetine old males, COF: control old females.
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Cerebellum
The permeability of the blood brain barrier was evaluated by using Evans blue
method. The evans blue was normalized by measuring the total ng of Evans blue and
dividing it by the protein concentration that was determined by using Bradford protein
assay. We saw a significant p value (<0.001) with an increased permeability in cerebellum
vs. hippo, cortex vs. hippo, and brain vs. hippo within SOF in figure 51. In figure 23, we
found a significant p value (0.0023). There was an increased permeability in the cerebellum
region of COF.
P-Value

The Animal
Groups

Significant difference

Increased permeability in Figure 51
cerebellum versus cortex,
<0.001 SOF vs. ROF
hippocampus or lower brain
Region
Cerebellum within SOF
Increased permeability of
Figure 23
0.0023 COF
cerebellum compared to other
brain regions
Table 8: Significant P-values for the cerebellum region of the brain. SOF: S-fluoxetine
treated old females; ROF: R-fluoxetine treated old females; COF: control old females
(old females without treatment).

4.4 The Treatment Effect among the Different Animal Groups
We used the total amount of normalized Evans blue to measure the blood brain
barrier permeability. In figure 55, the significant p value is 0.0353. We saw a decreased
permeability of COF vs. ROF whereas R-fluoxetine decreased the permeability in the
hippocampus region of the brain (Holm-Sidak post-hoc analysis). In figure 56, the
significant P value is 0.015. We saw a decreased permeability in COF vs. SOF whereas Sfluoxetine decreased permeability in the hippocampus region of the brain. In figure 42,
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which represents SYM vs. PYM, we saw an increased permeability in the cerebellum
region of the brain. In the brain region, we saw an increased permeability in young males
who have taken 5mg/kg of S-fluoxetine (Holm-Sidak post-hoc analysis).
P-Value

The Animal
Groups

Significant difference

Decreased permeability of in old Figure 55
0.0353 COF vs. ROF
Treatment
female rats that took Rfluoxetine
Increased permeability in old Figure 56
Treatment
female rats that took S0.015 COF vs. SOF
and region
fluoxetine in the cerebellum
interaction
only
Increased permeability in the Figure 42
0.046 SYM vs. PYM
cerebellum
Treatment
Increased permeability in young Figure 62
0.040 Brain
males who have taken 5 mg/kg
of S-fluoxetine
Table 9: Significant P-values for Treatment Effect. COF: Control Old Females; ROF: Rfluoxetine Old Females, SOF: S-fluoxetine Old Females; SYM: S-fluoxetine Young
Males; PYM: Prozac Young Males

4.5 The Activity of the Fluoxetine Metabolites
The S-fluoxetine enantiomer is metabolized principally to the S-norfluoxetine,
whereas the R-fluoxetine is metabolized to the R-norfluoxetine. The S-enantiomers show
stronger action when compared against the R-enantiomer forms: about 1.5 times higher for
the fluoxetine forms, and 20 times as much for norfluoxetine (120, 121). In other words,
the S-norfluoxetine is active, while the R-norfluoxetine is relatively inactive.
Previous studies have demonstrated that fluoxetine and norfluoxetine get passed
from the mother to the fetus through the placenta. Also, the serum of the newborn will
contain the medications and its metabolites even after its birth. In regard to the potential
pharmacological actions of the drug, the selective disposition of fluoxetine show more
123

impact on the foetus than on the mother specifically the S-norfluoxetine (122). Studies
have showed the presence of fluoxetine and its active metabolites in the brain and the
serum of the Sprague Dawley rats (106, 107) with the presence of norfluoxetine found in
brain samples over 2 weeks after the drug fluoxetine was given in a single dose.
Effect of Fluoxetine on Connexin 43
Astrocytes from the striatum have less number of functional channels formed by Connexin
43 than the astrocytes of the hypothalamus. Immunoblotting was used to determine the
amount of Cx43. It was found that the Cx43 protein in the hypothalamus is approximately
four times than that found in cultures from striatum. Northern blot analysis showed that
connexin 43 mRNA levels were also approximately 4-fold greater in the hypothalamic
cultures consistent with the difference seen by immunoblotting (123). In the prefrontal
cortex, other labs have found that fluoxetine increases Cx43 protein expression.
Antidepressant like behavioral activities results when Cx43 gets knocked down. Research
studies found that Fluoxetine and Corticosterone have opposite effects. Corticosterone
increases the hippocampal amounts of phosphorylated form of Cx43. Also, it caused
anxiety and depression-like abnormalities. Fluoxetine exhibit an opposite effect of
corticosterone. Antidepressant drugs provide therapeutic activity by decreasing the
expression of Cx43. Anawa trading was used to purchase Fluoxetine hydrochloride. The
medicine was used for one month. The concentration of fluoxetine was 18 mg/kg per day.
Old male transgenic were during this research study (124).
Our results showed that R-fluoxetine caused a decrease in permeability compared to
control in old female rats. That provided us an evidence that fluoxetine is more effective
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in females. Dr. Debra found out that there is an increase in connexin 43 in the hippocampus.
However, during this research study the medications were administrated for three days that
might was not enough period to cause a change in connexin 43 density. Also, fluoxetine
stimulates VEGF (vascular endothelial growth factor) which enhances the blood brain
barrier permeability because it increases angiogenesis (125).
4.6 Previous Research Studies
In a thesis named, Examination Of a Post-stroke Drug Treatment For Its Effect on
Blood Brain Barrier Permeability, and Gene Expression Changes in the Prei-infarct Region”
The blood brain barrier permeability was quantified by using Evans blue method after stroke
induction. The animals of this research study had stroke (brain injury) while the animals of
our research study were healthy and did not suffer from brain injury. Also, in our research
study we did not use unpaired-t-test with Welch’s corrections while this research study used
unpaired-t-test with Welch’s corrections. The animals that was used in this study were aged
animals (10-12 months old) while in our study both old (10-12 months) and young animals
(1.5 months) were used.
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Figure 66: Blood brain barrier permeability measurement in the cerebral cortex of the
males and the females’ animal groups.
The above figure shows the measurement of the blood brain barrier permeability in
the cortex of both the male and female rats. No outlier was found by using the ROUT
analysis. The data shows that there was significant difference in the results. The p-value was
0.0091. The male S-fluoxetine showed the least amount of the blood brain barrier
permeability in comparison to the other groups. The graph shows that the male and the
female rats that have taken S-fluoxetine showed less blood brain barrier permeability than
the R-fluoxetine. Unpaired t-test with Welch’s corrections showed the p-value for the female
S-fluoxetine and the female R-fluoxetine are significantly different. The p-value for that test
was 0.0041. Also, the unpaired t-test with Welch’s corrections showed that the male Sfluoxetine is significantly different from the male R-fluoxetine with a P-value of 0.0045.
That confirms that the S-fluoxetine decreased the blood brain barrier permeability while the
R-fluoxetine increased the blood brain barrier permeability. When we saw significant effects
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of the drug treatments in normal brains, we saw basically the opposite of these results: the
R-fluoxetine tightened the BBB compared to controls, and the S-Fluoxetine increased the
permeability of the BBB compared to controls in the cerebellar region of old female rats.
We believe that the fluoxetine is working on activated microglia in the injured brain, turning
them into beneficial M2 microglia, which support neuronal survival. In a normal brain, one
might expect more inflammatory microglia as an animal ages (126), but the overall effect
would be very different from an injured animals in terms of the sheer number of activated
microglia.
In this research study, we saw a tight BBB in both cortex and hippocampus of all animals tested.
Our 10 months rats corresponded to about 45 years old person. Neurodegenerative changes occur
generally after 65 years of age (human). So, we would like to evaluate older animals to see if we
see an increased in BBB permeability.

V. Future Directions
For future experiments, the remaining pellets of the experiment are still available
and we kept them at -80 freezer. For future experiments, we could look for the density of
the proteins that are found in the tight junctions such as ZO-1, and Cx43. Also, we could
possibly continue the work of Dr. Debra Mayes while she is looking for the density of
Cx43 and the level of estrogen. In addition, we interested to see if we could find a shift in
tight junction proteins that corresponds to the changes in BBB permeability that we see.
Also, we would like to use older animals (24 months old) to see if we could see an increased
BBB permeability.
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VI. Conclusion

In this study, we found out that there were regional differences in blood brain barrier
permeability in rats at all ages examined, with the hippocampal region generally showing
the tightest BBB. As we expected in the hypotheses with aging the blood brain barrier
permeability changes. Younger animals showed enhanced BBB permeability in the lower
brain region compared to older animals, which may reflect age related changes to the
choroid plexus region. We also saw that old female rats had enhanced BBB permeability
in the cerebellum, which may possibly be due to estrogen loss, but we would need to test
the BBB permeability in young female rats to make that conclusion. When we saw the
fluoxetine enantiomer treatment effects, they were generally opposite what we had seen in
injured rats (stroked rats): The R-fluoxetine seemed to tighten the BBB barrier and the Sfluoxetine loosened the BBB in the cerebellum in old female rats. In a model BBB that was
used in Dr. Maye’s lab, endothelial cells and astrocytes were the only cells that were
present at the model. The results of Dr. Maye’s showed that R-fluoxetine tightened the
BBB while S-fluoxetine increased permeability of the BBB. Microglia play a role in live
animal. So our results did not matches our expectations from the hypothesis about stroke
studies. In stroke models, microglial are activated and we see that S-fluoxetine tightening
the BBB while R-fluoxetine increased permeability. The long-lasting S-fluoxetine and Snorfluoxetine act to suppress inflammatory response from the microglia in this case. Since
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R-fluoxetine is only active a short time, the microglial can become inflammatory again
within a short time (hours). In the animals in this study, the microglia probably are not
activated or inflammatory. So fluoxetine might be working directly on the endothelial cells
or astrocytes. Interestingly, the R-fluoxetine and S-fluoxetine worked in the same way as
Dr. Mayes saw in her model BBB. We have negative Evans blue because we used the linear
regression line. It is the best fitting line for the data. The y-intercept for the line was 15
which was equivalent to zero. Any value less than 15 represents a negative number which
means that it is negative relative to the other Evans blue values.
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